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1 Summary 
 
In humans, chemical solutes are selectively transported from the intestinal 
lumen into polarized intestinal epithelial cells. This intestinal absorption of drugs, 
nutrients and bile acids is mediated by uptake transporter proteins expressed in the 
apical enterocyte membranes. Expression levels of the intestinal transporters 
contribute to the degree of absorption of their substrates. They are important 
determinants for pharmacokinetics of many drugs and are frequently altered in 
diseases of the intestine, such as inflammatory bowel disease. Changes in transporter 
expression mediated by transcription factors may contribute to pathological 
processes or lead to aberrant drug absorption in affected patients. 
The peptide transporter 1 (PEPT1) mediates uptake of di-/tri-peptides and 
peptidomimetic drugs in the small intestine. In patients suffering from chronic 
inflammation of the intestine, PEPT1 is aberrantly expressed in the colon. The 
transcriptional regulatory mechanisms leading to this dysregulation is unknown.  
A transcription factor which plays a pivotal role in chronic intestinal inflammation 
etiology is the peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ 
binds as a heterodimer together with its heterodimerization partner retinoid X 
receptor α (RXRα) to palindromic DNA sequences within a target promoter and 
regulates the target gene expression. As the ability of PPARγ to regulate the 
human/rodent PEPT1/Pept1 genes remains unelucidated, promoter activities of the 
human and rodent PEPT1/Pept1 genes were comparatively studied in the intestine-
derived cell line Caco-2.  
In silico analysis revealed several putative PPARγ binding sites within the 
human and rodent promoters. Several human and rodent PEPT1/Pept1 promoter 
constructs covering the putative PPARγ binding sites were cloned into pGL3Basic 
vectors containing luciferase genes to detect them by luminescence. Cells were co-
transfected with the luciferase-linked PEPT1/Pept1 promoter constructs and the 
expression plasmids encoding the PPARγ and RXRα genes. The reporter activities 
were measured by dual luciferase assays. PPARγ and RXRα proteins were translated 
in vitro and incubated with double-stranded oligonucleotides containing putative 
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PPARγ:RXRα binding sites of the PEPT1/Pept1 promoter sequences. Complexes 
formed in these electrophoretic mobility shift assays (EMSAs) indicated a specific 
DNA binding by PPARγ:RXRα heterodimers.  
In the presence of their respective ligands 15-deoxy-Δ12,14-prostaglandin J2 
and 9-cis retinoic acid, the human and rat PEPT1/Pept1 promoters were activated by 
PPARγ and RXRα. In contrast, the mouse Pept1 promoter failed to respond. These 
results were shown in co-transfection assays, EMSAs employing in vitro translated 
proteins, Caco-2 cells transfected with expression plasmids for PPARγ and RXRα, 
and in rat ileal explants treated with ligands of PPARγ and RXRα. Despite these 
obtained results further analysis of the human and rat PEPT1/Pept1 promoter with 
promoter constructs containing mutated PPARγ:RXRα DNA consensus regions to 
prevent the binding of the heterodimers and treatment of Caco-2 cells with specific 
ligands for PPARγ and RXRα to increase the PEPT1 mRNA did not change the 
activities of the promoters or the PEPT1 mRNA levels. It can be concluded that the 
human and rat PEPT1/Pept1 promoters are both regulated by PPARγ and its 
heterodimerization partner RXRα. Whether this transcriptional regulation has an 
effect on the protein expression and transport activity of human and rat 
PEPT1/Pept1, needs further investigations. 
Unlike PEPT1/Pept1, the organic anion transporting polypetides 
(OATPs/Oatps) are influx transporters with a broad spectrum of amphipathic 
substrates. They are widely expressed in human and rodent tissues. Due to their 
broad substrate specificity and tissue distribution they play a pivotal role in the 
pharmacokinetics of endogenous or exogenous compounds. It is known that the 
expression of some OATP/Oatp family members is influenced by vitamin D3, the 
hepatocyte nuclear factor 1 α, the hepatocyte nuclear factor 3 β, the pregnane X 
receptor, the farnesoid X receptor and by chronic inflammatory conditions of the 
human intestine.  
To understand the molecular mechanism that governs the transcriptional 
regulation of OATPs/Oatps, in silico analysis of the mouse Slco1a1 and Slco1a4 
promoters were performed and several potential binding sites of pregnane X 
receptor (Pxr) and the glucocorticoid receptor (GR) were found. In further 
experiments, liver explants from two mice strains were incubated in media 
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containing agonists of Pxr (pregnenolone-16α-carbonitrile, dexamethasone, 
hyperforin), GR (dexamethasone) and an antagonist of GR (mifepristone). There was 
a clear tendency that the addition of pregnenolone-16α-carbonitrile and 
dexamethasone led to higher mRNA levels of Oatp1a1 and Oatp1a4 expressed in 
specimens of both strains. The addition of mifepristone and hyperforin did not result 
in a lower or higher Oatp1a1 and Oatp1a4 mRNA concentration. To further elucidate 
the transcriptional mechanisms that led to increased mRNA expression of the Slco1a1 
and Slco1a4 genes, different promoter constructs of the Slco1a1 and Slco1a4 genes 
covering consensus regions of Pxr and GR were cloned into luciferase-linked 
pGL3Basic vectors. In co-transfection assays, the mSlco1a1 promoter construct was 
activated by the mouse GR (mGr) and the mouse Pxr (mPxr) together with its 
heterodimerization partner mouse Rxrα in the human liver derived cell line HuH-7. 
The co-transfection of the mouse small heterodimerization partner (Shp), a repressor 
of other transcription factors activity, led to an increase of mSlco1a1 promoter activity 
in the mouse liver derived cell line TIB-75. The mouse Slco1a4 promoter was not 
activated in human and mouse liver derived cell lines by the human and mouse 
GR/Gr, PXR/Pxr and the human FXR or mouse Shp. Further molecular 
investigations are needed to completely understand the regulatory pathways 
controlling the mSlco1a1 promoter activation by mouse Gr, Pxr:Rxrα and Shp. The 
mSlco1a4 promoter activity needs a deeper analysis of potential transcription factors 
controlling the expression of the mSlco1a4 gene. 
 
 
2 Zusammenfassung 
 
Nährstoffe, Arzneimittel oder körpereigene chemische Verbindungen wie z.B. 
Gallensalze werden aus dem menschlichen Darmlumen in Epithelzellen 
aufgenommen und von dort in den Blutkreislauf weitergegeben. Dies ist ein 
hochselektiver Prozess, welcher von Transportern, die in der Zellwand der 
Epithelzellen lokalisiert sind, gesteuert wird. Die aufgenommene Substratmenge und 
die Pharmakokinetik der einzelnen Substrate hängt somit stark von der Expression 
der entsprechenden Transporter in den Epithelzellen ab. Es ist bekannt, dass die 
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Expression durch den Gesundheitszustand des Darms reguliert wird. Bei 
entzündlichen Prozessen im Darm, wie z.B. chronisch entzündlichen 
Darmerkrankungen (Colitis ulcerosa, Morbus Crohn), kann die Expression der 
Transporter verändert sein. Dabei spielen Transkriptionsfaktoren eine wichtige Rolle. 
Durch sie kann die Genexpression der Transporter verändert und sowohl das 
Krankheitsbild beeinflusst werden wie auch zu einer veränderten Absorption von 
Medikamenten führen. 
Der Peptidtransporter 1 (PEPT1) transportiert normalerweise Di- und 
Tripeptide oder Peptidomimetika. PEPT1 wird beim gesunden Mensch im 
Dünndarm exprimiert. Bei Patienten mit einer chronischen Entzündung des Darms 
wird dieser Transporter zusätzlich im Dickdarm exprimiert. Die Mechanismen, 
welche zu dieser transkriptionellen Dysregulation führen, sind bisher unbekannt. Ein 
Transkriptionsfaktor, welcher eine entscheidende Rolle bei chronischen 
Entzündungen des Darms spielt, ist der sog. ‚peroxisome proliferator-activated 
receptor γ‘ (PPARγ). PPARγ bindet als ein heterodimerer Proteinkomplex zusammen 
mit dem ‚retinoid X receptor α‘ (RXRα) an palindromische Sequenzen der DNA. 
Diese Sequenzen befinden sich unter anderem in der Promoterregion von Genen, 
welche Transportproteine kodieren. Durch die Bindung des Proteinkomplexes kann 
die Expression eines solchen Genes erhöht oder erniedrigt werden. Es ist bisher nicht 
bekannt, ob PPARγ die Expression des humanen PEPT1 oder des Pept1 Gens von 
Nagern beeinflussen kann. Aus diesem Grund wurde in der vorliegenden Studie 
untersucht, ob  PPARγ an die Promoterregion des humanen PEPT1 oder des Pept1 
Gens von Nagern bindet und die Genexpression beeinflussen kann. Die Studien 
wurden in humanen Caco-2 Zellen durchgeführt. In silico Untersuchungen zeigten, 
dass mehrere potentielle Bindungsstellen für PPARγ im humanen wie auch in 
Nagetier (Maus, Ratte) PEPT1/Pept1 Promotoren vorhanden sind. Es wurden 
Promoterkonstrukte mit verschiedenen Bindungsstellen in den pGL3Basic Vektor 
kloniert, welcher ein Luziferase-Gen zur Lumineszenzanalyse exprimiert. Im 
pGL3Basic Vektor war die Expression des Luziferase-Gens unter direkter Kontrolle 
der Promoterkonstrukte, welche in den Vektor kloniert werden. Caco-2 Zellen 
wurden mit den humanen PEPT1 und den Pept1 Promoterkonstrukten der Maus und 
Ratte zusammen mit den Expressionsplasmiden für PPARγ und RXRα transfiziert, 
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um die Promoteraktivität der pGL3Basic Vektoren zu bestimmen. Beide Proteine, 
PPARγ und RXRα, wurden in vitro translatiert und mit zweisträngigen 
Oligonukleotiden, welche die möglichen Bindungsstellen des PEPT1/Pept1 
Promoters für PPARγ:RXRα Heterodimere enthielten, inkubiert. Die eingegangenen 
Komplexe wurden mittels 32P-Markierung sichtbar gemacht und anhand ihrer 
Grösse mittels Gelelektrophorese aufgetrennt (EMSA). Diese Methode zeigte, dass 
eine spezifische Bindung der Oligonukleotide durch in vitro translatierte 
PPARγ:RXRα Heterodimere stattfand. 
Es konnte gezeigt werden, dass der humane PEPT1 und der Pept1 Promoter 
der Ratte durch PPARγ:RXRα Heterodimere aktiviert wurde. Im Gegensatz dazu 
wurde der Pept1 Promoter der Maus nicht aktiviert. Dieses konnte in verschiedenen 
Versuchen gezeigt werden, wie: Co-Transfektionen, EMSA-Versuchen mit in vitro 
translatierten Proteinen, Caco-2 Zellen transfiziert mit Expressionsplasmiden für 
PPARγ und RXRα und behandelt mit deren Agonisten, Proben aus dem Ileum von 
Ratten behandelt mit PPARγ und RXRα Liganden. In Experimenten, bei denen die 
Bindungsstellen im humanen oder im Promoter der Ratte mutiert waren, um eine 
Bindung von der PPARγ:RXRα Heterodimere zu verhindern, wurden die 
Promotoren trotzdem aktiviert. Die Zugabe von PPARγ und RXRα Agonisten in das 
Zellmedium von Caco-2 Zellen führte zu keiner Erhöhung der PEPT1 mRNA. 
Zusammenfassend lässt sich sagen, dass die Aktivität des humanen und des 
Promoters der Ratte durch die Bindung von PPARγ:RXRα Heterodimeren gesteigert 
wurde. Ob dies eine Auswirkung auf die Proteinexpression oder die 
Transportaktivität von PEPT1 und rPept1 Proteinen hat, benötigt weitere 
Experimente. 
Die ‚organic anion transporting polypetides‘ (OATP/Oatps) sind ebenfalls 
Aufnahmetransporter. Sie transportieren jedoch amphipathische statt 
peptidomimetische Substanzen. Im Mensch und in Nagern sind die OATP/Oatps in 
zahlreichen Zellen und Organen exprimiert. Wegen ihren zahlreichen Substrate und 
der hohen Exprimierung spielen sie eine wichtige Rolle in der Pharmakokinetik von 
endogenen oder exogenen Verbindungen. Bisher ist bekannt, dass die Expression der 
OATP/Oatps durch Vitamin D3, den ‚hepatocyte nuclear factor α‘, den ‚hepatocyte 
nuclear factor 3 β‘, den ‚pregnane X receptor‘, den ‚farnesoid X receptor‘ und durch 
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chronische Entzündungen des Darms beeinflusst wird. Es sind jedoch nur wenige 
Kenntnisse über die molekularen Mechanismen, welche zu diesen transkriptionellen 
Veränderungen führen, vorhanden. Deshalb wurde eine in silico Analyse der Slco1a1 
und Slco1a4 Gene der Maus durchgeführt, die zur Auffindung mehrerer 
Bindungsstellen für die beiden Transkriptionsfaktoren ‚pregnane X receptor‘ (Pxr) 
und ‚glucocorticoid receptor‘ (GR) führte. 
Basierend auf diesen Erkenntnissen wurden Leberproben von 2 
Mäusestämmen in Zellkulturmedien inkubiert, welche Agonisten für Pxr 
(Pregnenolon-16α-carbonitril, Dexamethason, Hyperforin) und GR (Dexamethason), 
sowie einen Antagonisten für GR (Mifepriston) enthielten. Danach wurde die Slco1a1 
und Slco1a4 mRNA mit real-time PCR analysiert. In beiden Stämmen führte die 
Zugabe von Pregnenolon-16α-carbonitril und Dexamethason zu einer erhöhten 
Expression der Slco1a1 und Slco1a4 mRNA. Die Zugabe von Mifepriston und 
Hyperforin bewirkte jedoch keine Veränderungen der Slco1a1 und Slco1a4 mRNA. 
Verschiedene Promoterkonstrukte, welche mögliche Pxr und GR Bindungsstellen der 
Slco1a1 und Slco1a4 Promotoren enthielten, wurden in den pGL3Basic Vektor 
kloniert und die Aktivität der Promoterkonstrukte mit Chemolumineszenz 
analysiert. Es konnte gezeigt werde, dass in Co-Transfektionen der Slco1a1 Promoter 
durch GR und durch Pxr zusammen mit seinem Heterodimerisationspartner Rxrα in 
der humanen Leberzelllinie HuH-7 aktiviert wurde. In Co-Transfektionen in einer 
Leberzelllinie von Mäusen, TIB-75, führte die Zugabe des ‚small heterodimerization 
partner‘ (mShp), eines Repressors von Transkriptionsfaktoren, zu einer erhöhten 
Aktivität des Slco1a1 Promoters. In humanen oder Leberzelllinien der Maus zeigte 
der Slco1a4 Promoter keine erhöhte Aktivität durch Zugabe von GR/mGr, 
PXR/mPxr, FXR oder mShp Expressionplasmiden zu Co-Transfektionen. Weitere 
Experimente sind nötig, um die  Aktivierung des Slco1a1 Promoters durch mGr, 
mPxr:mRxrα und mShp zu klären. Im Falle des Slco1a4 Promoters müssen eventuell 
andere Transkriptionsfaktoren in Betracht gezogen werden, welche Einfluss auf die 
Transkription haben könnten. 
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3 List of abbreviations and ligands 
 
9-cis-RA: 9-cis-retinoic acid (agonist of RXRα) 
15d-PGJ2: 15-deoxy-Δ12,14-prostaglandin J2 (agonist of PPARγ) 
γ-globulin: bovine γ-globulin 
acrylamide/bis: acrylamide and bis-acrylamide solution 
ACE: angiotensin converting enzyme 
AHPN: 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (agonist 
of mShp) 
ASBT: apical sodium-dependent bile acid transporter 
ATCC: American Type Culture Collection 
ATG: adenosine thymidine guanosine (start of translation) 
APS: ammonium peroxo disulfate 
BCA: bicinchoninic acid 
Carb: carbenicillin 
CDCA: chenodeoxycholic acid (agonist of FXR) 
CER I: cytoplasmic extraction reagent I 
CER II: cytoplasmic extraction reagent II 
ChIP: chromatin immunoprecipitation 
Ciprofibrate (agonist of PPARα) 
CO2/RH: carbon dioxide/relative humidity 
cpm: counts per minute 
Ct: cycle threshold 
DCA: deoxycholic acid 
ddH2O: double distilled water 
Dexamethasone (agonist of GR and PXR) 
dGTP/dCTP/dTTP: mixture of desoxyguanosine triphosphate/ desoxycytosine 
triphosphate/ desoxythymidine triphosphate 
DMEM: Dulbecco’s Modified Eagle Medium 
DMSO: dimethyl sulfoxide 
DPDPE: (2-D-penicillamine, 5-D-penicillamine)-enkephalin 
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DR motif: direct repeat motif 
DTT: dithiothreitol 
EGF: epidermal growth factor 
EMSA: electromobility shift assay 
ER: estrogen receptor 
ER motif: everted repeat motif 
FBS: fetal bovine serum 
FXR: farnesoid X receptor 
GR: glucocorticoid receptor 
GW-9662 (antagonist of PPARγ) 
GW-1929 (agonist of PPARγ) 
HGNC: HUGO Gene Nomenclature Committee 
HNF1α: hepatocyte nuclear factor 1 α 
HNF3β: hepatocyte nuclear factor 3 β 
HNF4α: hepatocyte nuclear factor 4 α  
HRP: horse radish peroxidase 
HUGO: Human Genome Organization 
Hyperforin (agonist of PXR) 
IBD: inflammatory bowel disease 
IFNγ: interferon γ 
IR: inverted repeat motif 
LB: lysogeny broth 
LCA: lithocholic acid 
MDR: multidrug resistance protein 
Mifepristone (antagonist of GR) 
MK-886 (antagonist of PPARα) 
Motif: specific DNA sequence bound by a transcription factor 
MRP: multidrug resistance-related protein 
MRP2: multidrug resistance-related protein 2 
Na+/K+-ATPase: sodium/potassium adenosine-5'-triphosphatase 
NER: nuclear extraction reagent 
NTCP: sodium taurocholate co-transporting polypeptide 
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OATP: organic anion transporting polypeptide 
PBS: phosphate buffered saline 
PCN: pregnenolone-16α-carbonitrile 
PCR: polymerase chain reaction 
PEPT1: peptide transporter 1 
PG: prostaglandin 
PIC: protease inhibitor cocktail 
PMSF: phenylmethane sulfonylfluoride 
poly(dI-dC)-poly(dI-dC): poly(deoxyinosinic-deoxycytidylic)-poly(deoxyinosinic-
deoxycytidylic) acid  sodium salt 
PPAR: peroxisome proliferator-activated receptor 
PPARα: peroxisome proliferator-activated receptor α 
PPARγ: peroxisome proliferator-activated receptor γ 
PPRE: peroxisome proliferator-activated receptor response element 
PXR: pregnane X receptor 
RIPA: radioimmunoprecipitation assay 
rcf: relative centrifugal force 
RISC: RNA-induced silencing complex 
rpm: revolutions per minute 
RT: room temperature (~22 °C) 
RXRα: retinoid X receptor α 
SD: standard deviation 
SHP: small heterodimer partner 
siRNA: small interfering RNA 
SLC: solute carrier 
TBE buffer: Tris-Borate-EDTA buffer 
TEMED: tetramethylethylenediamine 
TM: transmembrane 
TNFα: tumor necrosis factor α 
Troglitazone (agonist of PPARγ) 
Trizma: 2-Amino-2-(hydroxymethyl)-1,3-propanediol 
VDR: vitamin D receptor 
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WY-14643 (agonist of PPARα) 
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4 Introduction 
 
Lipid bilayers of cells separate the intracellular space from the extracellular 
environment and are essential for the functioning of living cells. Depending on the 
chemical structure of a compound, this bilayer can be an obstacle for molecules that 
is extremely difficult to cross. However, cells have to take up and excrete selectively 
or unselectively nutrients, waste products and signaling molecules from the 
extracellular into the intracellular space or vice versa. Most lipophilic compounds 
can cross biological membranes through diffusion, not so hydrophilic or charged 
compounds which poorly pass the lipid bilayer this way. They have to be 
transported across the lipid barrier with the support of integral proteins.  
The simplest way of transport is diffusion which does not require integral 
proteins coupled to a biochemical energy source. If the transport requires energy to 
drive the influx or efflux via membrane proteins or simply needs proteins as a 
hydrophilic gate in the membrane, three types of transport mechanisms can be 
distinguished. First a membrane protein can form a pore which is always open, as 
shown for perforin. Originally hypothesized by Podack and co-workers (Podack et 
al., 1984), it is today known that perforin inserts itself into the target cell membrane 
forming a pore which allows granzymes to influx into the cell and induce apoptosis 
(Voskoboinik et al., 2006, Law et al., 2010). This pathway represents a transport 
mechanism which is called passive transport because it does not require an energy 
source for the functioning of the membrane protein since the flux of the solutes 
follows the concentration gradient.  
A second transport mechanism requires transporters coupled to energy 
sources. By this way the transport of solutes is possible against the concentration 
gradient. Energy requiring transporters can again be divided into two different 
groups. First, carriers can be coupled to an electron transport chain or the hydrolysis 
of ATP (e.g. Na+/K+-ATPase). Each carrier protein has a specific affinity to one or 
several solutes and transports them across the membrane bilayer. Second, carriers 
which are not coupled to an electron transport chain or do not hydrolyze ATP are 
called solute carriers (SLCs). They receive their energy by coupling the uphill 
transport of a solute with the downhill transport of another solute. The SLC 
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superfamily is classified according to the homology of the amino acid sequences. 
Currently it includes 51 families and 378 transporter genes. The nomenclature system 
was proposed by the HUGO Gene Nomenclature Committee (HGNC) (Wain et al., 
2002) and represents the names of the genes that encode the transporters. Members 
within a SLC family have at least 20-25% amino acid sequence homology to each 
other. Numerous SLC transporter gene defects have been identified and shown to 
lead to disease symptoms or to cause pathophysiological conditions in the 
metabolism thus supporting the urgent need for research in this field. For example, 
defects in the human apical sodium-dependent bile acid transporter ASBT result in 
malabsorption of bile acids in the ileum (Oelkers et al., 1997). The absence of MRP2 in 
human hepatocytes leads to the Dubin-Johnson syndrome, an autosomal recessive 
disorder causing conjugated hyperbilirubinemia (Wada et al., 1998). Another 
example is the cystic fibrosis that is characterized by an abnormal function or absence 
of the cystic fibrosis transmembrane conductance regulator (Riordan et al., 1989) 
severely affecting the lung, pancreas, intestine and liver of patients. 
Organic anion transporting polypeptides (OATPs) are sodium independent 
influx transporters of the SLCO21 family with a broad spectrum for amphipathic 
substrates. Extensively studied in humans, they are expressed in the liver, blood-
brain barrier, choroid plexus, lung, heart, intestine, kidney, placenta and testis 
(Tamai et al., 2000). Due to their broad substrate specificity they play a pivotal role in 
the pharmacokinetics of endogenous and exogenous compounds. Their substrates 
include bile salts (Kullak-Ublick et al., 1994, Eckhardt et al., 1999, Reichel et al., 1999), 
organic dyes (van Montfoort et al., 1999), thyroid hormones (Friesema et al., 1999) 
and steroid conjugates (Eckhardt et al., 1999, Reichel et al., 1999, Bossuyt et al., 1996, 
Kanai et al., 1996a, Kanai et al., 1996b) among others. Together with the multidrug 
resistance proteins (MDRs) and the multidrug resistance-related proteins (MRPs) 
they play an important role in the context of drug uptake and excretion.  
The driving force of OATPs/Oatps to transport their substrates is not sodium 
dependent (Jacquemin et al., 1994, Noé et al., 1997, Walters et al., 2000) like ASBT or 
the sodium taurocholate co-transporting polypeptide NTCP. Shi and co-workers (Shi 
et al. 1995) found a bidirectional transport of sulfobromophthalein in rat Oatp1a1 
expressing HeLa cells.  Satlin and co-workers (Satlin et al., 1997) studied the 
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taurocholate/hydrogencarbonate exchange by rat Oatp1a1 in HeLa cells. 
Hydrogencarbonate can be suggested as the extruded anion, but other ions are also 
possible for the exchange in vitro. For instance glutathione has been shown to 
contribute to this uptake (Li et al., 1998). 
In recent years, 36 OATPs/Oatps have been identified and classified in 
agreement with the HGNC recommendations in human, mice and rats. 
OATPs/Oatps within the same family share ≥40% amino acid sequence identities 
and are designated with numbers from 1 to 6 (OATP1 to OATP6). The subfamilies 
include OATPs/Oatps with amino acid sequence of ≥60% identities. Letters are used 
to label the different subfamilies (e.g. OATP1A, OATP1B, OATP1C, etc.). Individual 
proteins within the same subfamily are designated with numbers (e.g. OATP1A2, 
Oatp1a1, Oatp1a3, etc.). The OATP1 family consists of four subfamilies. The three 
subfamilies OATP1A/Oatp1a, OATP1B/Oatp1b and OATP1C/Oatp1c contain 28 
individual genes in human, mice and rats. All OATPs/Oatps exhibit 12 
transmembrane (TM) domains based on hydropathy analysis (Jacquemin et al., 1994). 
They have an extracellular domain between the TMs 9 and 10 and two N-
glycosylation sites in the extracellular loop 2 and one in loop 5. Between the 
extracellular loop 3 and TM domain 6, a highly conserved consensus sequence was 
identified (Hagenbuch and Meier, 2003). This amino sequence is also known under 
the label ‘OATP superfamily signature’ and can be found in the mammalian species 
human, mouse and rat, but also in the phylogenetically rather distant Caenorhabditis 
elegans and Drosophila melanogaster.  
 
The OATP1A subfamily contains one human member, OATP1A2 (gene 
symbol SLCO1A2). It was originally cloned from a human liver cDNA library 
(Kullak-Ublick et al., 1995). The authors demonstrated that OATP1A2 has its 
strongest expression in the blood-brain barrier.  The liver and kidneys have a weaker 
expression. OATP1A2 has an apparent molecular mass of ~ 85 kDa (Kullak-Ublick et 
al., 1997), whereas in brain capillary endothelial cells its apparent molecular mass is 
~ 60kDa (Gao et al., 2000). OATP1A2 transports bile salts, steroid conjugates, 
prostaglandin E2, the endothelin receptor antagonist BQ-123, the thrombin inhibitor 
CRC-200, the opioid receptor agonists (2-D-penicillamine, 5-D-penicillamine)-
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enkephalin (DPDPE), deltorphin II, the antihistamine fexofenadine, the poisonous 
cardiac glycoside ouabain and the cyanobacterial toxin microcystin (Hagenbuch et 
al., 2003).  OATP1A2 has four mouse [Oatp1a1 (Hagenbuch et al., 2000), Oatp1a4 
(van Montfoort et al., 2002), Oatp1a5 (Walters et al., 2000), Oatp1a6 (Choudhuri et al., 
2001)] and four rat homologues [Oatp1a1 (Jacquemin et al., 1994), Oatp1a3 (Saito et 
al., 1996), Oatp1a4 (Noé et al., 1997), Oatp1a5 (Abe et al., 1998)] within the 
OATP1A/Oatp1a subfamily.  
The transcriptional regulation of several OATPs/Oatps has been studied in 
more detail. In Caco-2 cells treated with vitamin D3, the endogenous expression of 
OATP1A2 mRNA was induced through the vitamin D3 receptor at the transcriptional 
level (Eloranta et al., 2012). In hepatocyte-derived liver cell lines, Jung and co-
workers showed that the hepatocyte nuclear factor 1α (HNF1α) binds to its preferred 
DNA consensus region in the SLCO1B1 promoter and activates it (Jung et al., 2001). 
The transcriptional regulation of the SLCO1B3 gene was dependent on HNF1α (Jung 
et al., 2001) and in addition on the farnesoid receptor X (FXR) (Jung et al., 2002).The 
hepatocyte nuclear factor 3β (HNF3β) represses the transcription of the SLCO1B3 
gene shown by decreased levels of OATP1B3 mRNA and protein in hepatocellular 
carcinoma samples from patients (Vavricka et al., 2004). A possible link between 
inflammatory signaling and transcriptional regulation of OATPs in the human 
intestine was shown by Wojtal and co-workers (Wojtal et al., 2009). In the ileum and 
colon of IBD patients the mRNA levels of OATP2B1 and OATP4A1 were 
upregulated. Guo and co-workers found that in the rat liver cell line H4IIE, 
pregnenolone-16α-carbonitrile (PCN), a ligand of the rodent pregnane X receptor 
(PXR), induces rat Slco1a4 gene expression (Guo et al., 2002). Several PXR response 
elements were identified in the promoter region of rat the Slco1a4 gene. The binding 
of PXR together with its heterodimerization partner retinoid X factor α (RXRα) to 
these PXR response elements was shown in electrophoretic mobility shift assays. 
Luciferase assays confirmed the induction of the rat Slco1a4 promoter by the 
activation of PXR by PCN. Staudinger and co-workers showed that the bile acid 
lithocholic acid (LCA) activates PXR and regulates the expression of Oatp1a4 
proteins in mice (Staudinger et al., 2001). The mRNA and protein expression of rat 
Oatp1a4 was also increased in rats treated with phenobarbital for 5 days (Hagenbuch 
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et al., 2001). Phenobarbital, a PXR activator, is also an important inducer of several 
biotransformation enzymes like cytochrome P-450 monooxygenase (Waxman et al., 
1992) or gluthatione S-transferase (Pinkus et al., 1993). 
So far, only Oatp1a/1b knockout mice have been bred by van de Steeg and co-
workers (van de Steeg et al., 2012). But Oatp expression has been evaluated in several 
transcription factor knockout mice models. HNF1α knockout mice have decreased 
expression of Oatps in the liver (Shih et al., 2001). This results in impaired basolateral 
membrane bile acid uptake and augmented plasma bile acid concentrations. Mice 
with a conditional hepatocyte nuclear factor 4α (HNF4α) gene knockout in mature 
hepatocytes developed decreased expression levels of Oatp1a1 (Hayhurst et al., 
2001). These studies led to the assumption that HNF1α and HNF4α are important 
factors regulating Oatp expression in mice. FXR null mice fed with cholate showed 
increased Oatp1a1 expression (Sinal et al., 2000). The molecular regulatory 
mechanism of this induced expression is unknown. Oatp1a4 mRNA expression was 
increased upon treatment with PCN in wild type mice but not in PXR null mice 
(Staudinger et al., 2001). In several models of cholestasis such as bile duct ligation or 
ethinyl estradiol treatment, Oatp protein expressions were downregulated (Meier et 
al., 2002).  
Another family of uptake transporter is represented by the human ileal apical 
sodium dependent bile acid transporter ASBT (gene symbol SLCO10A2). ASBT 
belongs to the SLC10 family of solute carriers. It is the main reabsorptive transporter 
of bile acids from the intestinal lumen. The extent of absorption influences the bile 
acid pool size and the activity of the bile acid synthesizing enzymes cholesterol-7α-
hydroxylase and cholesterol-27-hydroxylase (Xu et al., 2000). The human ASBT 
protein was first cloned and detected by Craddock and co-workers in the terminal 
ileum, caecum and kidney (Craddock et al., 1998).  
ASBT transports conjugated and unconjugated bile salts and is sodium ion 
dependent. The affinity for chenodeoxycholic acid (CDCA) and deoxycholic acid 
(DCA) is higher than for taurocholate (Craddock et al., 1998). Jung and co-workers 
have shown that the peroxisome-proliferator activated receptor α (PPARα), activated 
by ciprofibrate (an anti-hypercholesterolemia drug), or the synthetic ligand WY14643 
binds to the so called direct hexanucleotide DNA motif (DR motif) of the ASBT 
16 
 
promoter and leads to an activation of the ASBT promoter in human colon derived 
Caco-2 cells. The nuclear receptor PPARα binds to the DNA motif as a heterodimer 
together with RXRα (Kliewer et al., 1992) 
Duane and co-workers revealed that patients with type IV 
hypertriglyceridemia exhibit decreased intestinal bile salt absorption (Duane et al., 
2000) and showed that the expression of ASBT mRNA and protein levels were 
significantly reduced in the intestine of patients. Fatty acids are known activators of 
PPARα which leads to the assumption of a link between lipid metabolism and bile 
salt absorption by ASBT. The glucocorticoid receptor (GR) is a well known 
transcriptional regulator of the SLCO10A2gene in humans. This nuclear steroid 
hormone receptor is activated by glucocorticoids such as dexamethasone and forms 
homodimers to bind the DNA motif. Jung and co-workers (Jung et al., 2004) showed 
the in vitro binding of two commonly used glucocorticoids, budenoside and 
dexamethasone, to two DNA response elements in the ASBT promoter region and 
found an activation of the promoter in Caco-2 and HuH-7 cells. Patients with Crohn’s 
disease, an inflammatory condition of the intestine, often have decreased ASBT 
protein levels and consequently suffer from bile acid malabsorption. It could be 
shown that patients under budenoside medication showed higher ASBT protein 
levels in the small intestine compared to patients without budenoside treatment, thus 
supporting the influence of glucocorticoids on the transcriptional regulation of the 
ASBT gene. 
A further family of uptake transporters transports mainly oligopeptides and is 
proton driven in contrast to the majority of the other uptake transporters which are 
sodium ion dependent. The human peptide transporter 1 (PEPT1), gene symbol 
SLC15A1, is located in the brush border membrane of the small intestine and to a 
lesser degree in proximal renal tubule cells (Fei et al., 1994). PEPT1 contains 12 
transmembrane domains predicted by hydropathy analysis (Covitz et al., 1998). 
Although the function of this transporter is primarily the absorption of di- and 
tripeptides, PEPT1 transports a wide spectrum of peptidomimetic substrates. 
Compounds such as the antitumour agent bestatin (Saito et al., 1996), the 
angiotensin-converting enzyme (ACE) inhibitor captopril (Zhu et al., 2000), the β-
lactam antibiotic cefadroxil (Boll et al., 1994) and the antiviral drug acyclovir (Han et 
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al., 1998) are substrates of PEPT1. The energy for the transport is generated by an 
inwardly directed proton flow (Biegel et al., 2006).  
PEPT1 has recently become of interest because its expression is regulated by 
nutrition and is involved in the obesity problem. The small intestinal Pept1 mRNA 
expression level increases when rats were fed a diet supplemented with high 
amounts of protein (Erickson et al., 1995). Shiraga and co-workers showed with the 
same rat model an increase in Pept1 protein levels and augmented uptake of 
dipeptides when the rats were fed with a high protein diet (Shiraga et al., 1999). The 
authors suggest that most likely the increase in Pept1 protein level is the result of 
promoter activation by dipeptides or by the amino acids phenylalanine, arginine or 
lysine. It has also been argued that the increase could be the consequence of more 
stable Pept1 mRNA (Walker et al., 1998). Pan and co-workers showed that starvation 
of rats over four days significantly increases the transport of the PEPT1 substrate 
ceftibuten (Pan et al., 2003). Habold and co-researches confirmed by immunostaining 
and western blotting that the Pept1 protein expression in rat enterocytes increased 
after twelve days of starvation (Habold et al., 2007). Nässl and co-authors (Nässl, et 
al., 2011) hypothesized a cross-talk of arginine and leptin signaling in mouse brain, 
which led to reduced food intake of Pept1 knockout mice over up to five days 
compared to wildtype control animals when fed with a high protein diet (45 protein 
energy percent). After five days the knockout mice did not show an increase in body 
weight despite a regain in food intake. A reduction in energy assimilation and 
augmented fecal energy loss on a high-protein diet were discussed. Plasma arginine 
levels were elevated in the knockout mice on high protein and normal protein diet 
compared to the wildtype mice, but the plasma leptin levels were reduced only in 
mice fed with a high protein diet.  
The PPARα synthetic ligand WY-14643 led to increased PEPT1/Pept1 mRNA 
expression when administered to Caco-2 cell layers and rats. Furthermore, the 
uptake of the dipeptide glycylsarcosine was augmented after treatment of Caco-2 
cells with the ligand. Comparing PPARα knockout and wildtype mice during fasting, 
the increase of Pept1 mRNA was not observed in the knockout mice (Shimakura et 
al., 2006). This study supports a possible role of PPARα in fasting-induced Pept1 
expression in rodents. 
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 The expression of the human and rodent PEPT1/Pept1 genes is also affected 
by several hormonal pathways. Hyperthyroidism decreases the intestinal Pept1 
expression in rats either through an interaction between the thyroid hormone and the 
rat Pept1 promoter, or by increasing Pept1 mRNA stability (Ashida et al. 2002, 
Ashida et al., 2004). Leptin increased PEPT1/Pept1 protein levels and transport 
activity of cephalexine into Caco-2 cells and in the small intestine of rats (Buyse et al., 
2001). Gangopadhyay and co-workers showed that diabetic rats had augmented 
Pept1 protein levels and transport activity in their brush border membrane and 
suggested a role of insulin in the transcriptional regulation (Gangopadhyay et al., 
2002). Addition of epidermal growth factor (EGF) to the medium of the cell culture 
led to a decreased uptake of glycylsarcosine into Caco-2 cells (Nielsen et al., 2001). 
Not only hormones seem to regulate PEPT1/Pept1 expression, but also ions like 
Ca2+, cytokines and drugs are involved in the regulation of the PEPT1/Pept1 genes. 
Decreased intracellular Ca2+ levels augmented absorption of cefixime mediated by 
PEPT1 into Caco-2 cells when they were treated with Ca2+ channel blockers like 
nifedipine and verapamil (Wenzel et al., 2002). In chronic states of inflammation in 
the human intestine, PEPT1 is expressed in specimens of inflamed colon, whereas it 
is not expressed in the healthy colon (Merlin et al., 2001). Vavricka and co-workers 
studied the uptake of glycylsarcosine into Caco-2 cells and in mice injected with 
cytokines. The tumor necrosis factor α (TNFα) and interferon γ (IFNγ) both increased 
PEPT1/Pept1 transport activity in the membrane (Vavricka et al., 2006). Pentazocine, 
a synthetic opioid, raised the transport activity of PEPT1 in Caco-2 cells by increasing 
PEPT1 mRNA in a dose-dependent manner (Fujita et al., 1999).  
 
Several examples have been found that the transcriptional regulation of genes 
encoding transporter proteins can lead to severe symptoms or cause diseases. Thus, 
the present thesis focuses on the better understanding of the molecular mechanisms 
governing transcriptional regulation of transporter genes encoding human and 
rodent OATPs/Oatps and PEPT1/Pept1 proteins. 
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5 Aims 
 
- To study whether the transcription of the SLC15A1 gene, encoding the 
protein PEPT1, is regulated by the peroxisome proliferator-activated 
receptor γ (PPARγ) and its heterdimerization partner retinoid X 
receptor α (RXRα). These studies include assays analyzing the PEPT1 
and the mouse and rat Pept1 promoter in silico and in vitro. Additionally 
assays measuring a potential effect of treatment of Caco-2 cells or ileal 
rat explants with ligands for PPARγ and RXRα on the PEPT1/Pept1 
mRNA expression in the cells are applied. 
 
- To study whether the mouse Slco1a1 and Slco1a4 promoters coding for 
Oatp1a1 and Oatp1a4 are transcriptionally regulated by the 
glucocorticoid receptor (GR), the pregnane X receptor (PXR) and the 
farnesoid X receptor (FXR) in human HuH-7 and HepG2 cells and in 
the mouse cell line TIB-75. The mouse isoforms of the human GR and 
PXR and the mouse Shp were included in these assays taking into 
account the potential species differences of the transcription factor 
isoforms. In silico and in vitro assays with the mSlco1a1 and mSlco1a4 
promoters and treatment of the human and mouse cell lines with 
ligands for the human and mouse GR/Gr, PXR/Pxr and the human 
FXR and the mouse Shp analyze a potential interaction of the 
transcription factors with the promoters. 
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6 Materials and Methods 
 
6.1 Chemicals, kits and instruments 
 
A list with all chemicals, kits and instruments including their manufacturers 
can be found at the end of section Materials and Methods. 
 
                                                                                                                                                                                                                                                                           
6.2 Origin and culture of cell lines 
 
Five human colonic (Caco-2, T84, LS 174T, HT-29 and DLD-1), 1 human 
duodenal (HuTu 80), 2 human hepatic (Hep G2, HuH-7), 1 mouse small intestinal 
(IEC4.1), 1 mouse hepatic (TIB-75) and 2 rat small intestinal (IEC-6, IEC-18) cell lines 
served as epithelial in vitro models. All human cell lines were routinely subcultivated 
in the lab. The rat cell lines were bought from LGC Promochem, Molsheim, France. 
The cell line IEC4.1 was a kind gift from Dr. A. Jevnikar from the Division of 
Nephrology, University of Ontario in Canada, whereas the cell line TIB-75 was 
generously provided by Dr. R. Graf from the Division of Visceral and Graft Surgery 
of the University Hospital of Zurich. All cell lines were handled and subcultivated 
according to the ATCC product information and in the case of IEC4.1 according to Li 
and co-workers (Li et al., 1997). 
 
 
6.3 RNA extraction  
 
Total RNA extraction from cells and rodent tissue samples was achieved by 
using the guanidine isothiocyanate and phenol containing reagent TRIzol. All 
samples were collected in 1.5 ml Safe-Lock tubes. TRIzol in quantities of 500 µl or 
1000 µl were applied to extract RNA from either 6-well, 12-well and 24-well Corning 
multiple well plates, 35- and 100-mm Corning dishes and specimens of mouse and 
rat tissue. Rat and mouse tissue explants from liver, kidney and the intestine were 
processed in 1.5 ml Safe-Lock tubes and broken by several passages through 18G x 1 
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½  ‘‘,  21G x 1 ½  ‘‘ and 22G x 1 ¼   ‘‘ needles followed by drawing up in a 1-ml U-100 
syringe. The tissue pieces were pipetted several times up and down the syringe to be 
homogenized as far as possible. Adherent cells were directly lysed in their culture 
dish wells by pipetting up and down and were then transferred to 1.5-ml Safe-Lock 
tubes. The volumes indicated in the following protocol are needed to extract RNA 
from a 1000 µl mixture of tissue or cultivated cells both suspended in TRIzol.  The 
volumes were divided into half whenever 500 µl of the TRIzol reagent were used. 
First, the homogenized samples were left at room temperature for 5 minutes 
for dissociation of the nucleoprotein complexes. The samples were vigorously mixed 
with 200 µl chloroform, incubated at room temperature for 2-3 minutes and 
centrifuged (12,000 g, 15 min, 4 °C). As in the following steps a microcentrifuge 5417 
R was used. As a result, 3 phases are formed. A lower protein, phospholipid and 
DNA containing phase, a DNA containing interphase and an upper aqueous phase 
where the RNA remained. The RNA was transferred to a 1.5 ml RNase-free 
Microfuge tube, and subsequently 500 µl isopropanol were added. The samples were 
stored at -20 °C for 10 minutes at least and centrifuged (14,000 rpm, 10 min, 4 °C). 
After removal of the supernatant, the RNA pellet was washed with 500 µl 75% 
ethanol and centrifuged (5 minutes with 14,000 rpm at 4 °C). The pellet was air-dried 
for 5-10 min and resuspended in 15-60 µl nuclease-free water depending on the 
A260/280 ratio (see Quantification of DNA/ RNA). 
 
 
6.4 Plasmid purification from Escherichia coli  
 
Medium scale 
Cultures of E. coli were grown in 50 ml LB broth/Carb overnight for 12-16 h. 
Plasmid DNA was extracted with the Qiagen Plasmid Midi kit from 50 ml bacterial 
lysate. The bacterial culture medium was replaced by 4 ml resuspension buffer P1 
after centrifugation (4000 rpm, 15 min, 4 °C, centrifuge 5810 R). The cells were lysed 
for 5 minutes in 4 ml sodium hydroxide containing buffer P2. After neutralization 
with 4 ml acetic acid buffer P3, the lysate was applied to a previously equilibrated (4 
ml buffer QBT) QIAGEN-tip. The plasmid DNA was collected due to gravity flow 
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through the resin of the column for 10 min. The resin was washed 2x with 10 ml 
wash buffer QC, and finally the DNA was eluted with 5 ml elution buffer QF into 
autoclaved plastic tubes filled with 3.5 ml isopropanol. The obtained DNA was 
precipitated by centrifuging (10,000 rpm, ≥ 30 min, 4 °C, Avanti J-E centrifuge). The 
pellet was dissolved in 400 µl Tris-EDTA buffer solution pH 7.4 and transferred to 
1.5-ml tubes. The DNA was precipitated with 1 ml 100% ethanol and 40 µl sodium 
acetate solution pH 5.0 at -20 °C for ≥ 30 min. The pellet was then washed with 70% 
ethanol and resuspended in 50 µl Tris-EDTA buffer solution. 
 
Small scale 
Cultures of E. coli were grown in 3 ml LB broth/Carb overnight for 12-16 h. 
The GeneJET Plasmid Miniprep Kit was used to purify plasmid DNA from 3 ml 
bacterial lysate. The cells were resuspended in 250 µl resuspension solution, lysed 
with 250 µl lysis solution and subsequently the lysis was stopped by adding 250 µl 
neutralization solution. The cell debris and chromosomal DNA were pelleted by 
centrifugation (13,000 rpm, 5 min, 4 °C, microcentrifuge 5417 R). The plasmid 
containing supernatant was transferred on a GeneJET™ spin column and centrifuged 
(1 min, 13,000 rpm, 4 °C, microcentrifuge 5417 R). The spin column membrane was 
washed 2x with 500 µl wash solution with subsequent centrifugations (13,000 rpm, 1 
min , 4 °C, microcentrifuge 5417 R). The plasmid DNA was finally eluted with 30 µl 
elution buffer and centrifugation (13,000 rpm, 2 min, 4 °C, microcentrifuge 5417 R). 
 
 
6.5 Glycerol stocks of bacterial cells 
 
Glycerol stocks of bacterial cultures were prepared in LB broth/Carb medium 
supplemented with glycerol (final glycerol concentration was 20% v/v). The cultures 
were transferred to CryoTube vials and then stored in a liquid nitrogen storage tank. 
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6.6 DMSO stocks of mammalian cell lines 
 
The cell line specific complete growth media were supplemented with another 
10% (v/v) fetal bovine serum and 10% (v/v) dimethyl sulfoxide (DMSO). The cells 
were suspended in this medium, put into a –80 °C freezer overnight and then stored 
in a liquid nitrogen storage tank. 
 
 
6.7 Quantification of DNA/ RNA 
 
The quantities of nucleic acids in all samples were determined by their ability 
to absorb ultraviolet light at the wavelength of 260 nm (spectrophotometer ND-1000).  
The purity of the samples was assessed by determination of the A260/280 ratio (partial 
overlapping of the absorption of nucleic acids at 260 nm and proteins at 280 nm). The 
ratio ranged between 1.8 and 2.0. 
 
 
6.8 Polymerase chain reaction 
 
Cloning of mammalian promoter sequences into reporter gene expressing 
vectors or transcription factor genes into expression vectors was done by using two 
different PCR kits. A typical reaction mix contained the target DNA, two primers 
complementary to the target DNA, a thermostable DNA polymerase and nucleotides. 
In most cases the in vitro amplification of specific DNA sequences was successful 
using illustra puReTaq Ready-To-Go PCR beads. However, DNA tends to form 
secondary structures fixed by hydrogen bonds between the purines and pyrimidines. 
These structures prevent the annealing of the primers and the binding and 
movement of the DNA polymerase along the template DNA towards the 5’ end. 
Especially regions with a high content of guanine and cytosine lead to strong 
interactions between nucleotides because the hydrogen bonds interact between them. 
Therefore, a special kit from Clontech Laboratories (Advantage-GC 2 PCR) was used 
whenever first PCR reactions with the puReTaq Ready-To-Go PCR beads failed to 
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amplify the region of interest. The advantages of this kit are the use of DMSO and 
GC-Melt in the buffer to disrupt base-pairing and a special polymerase mix 
containing Taq polymerase, a proofreading polymerase and TaqStart antibodies. The 
final GC-Melt concentration of a reaction mix differed from 0 to 1.5 M for each DNA 
region of interest. 
The cycling parameters were set as followed: 
 
Ready-To-Go beads:     Advantage-GC 2 PCR kit: 
(3 step cycles)      (2 step cycles) 
 
• 95 °C for 3 min      • 94 °C for 3 min  
• 40 cycles       • 40 cycles  
95 °C for 30 s       94 °C 30 s 
Primer annealing temperature for 30 s    68 °C 1 min/kb target 
72 °C 1 min/kb target  
• 72 °C 1 min/kb target      • 68 °C for 1 min/kb target 
• +4 °C        • +4 °C  
   
PCR products were visualised on 1% agarose gels stained with either SYBR - Safe 
DNA gel stain (0.01%, v/v) or GelRed stain (0.01%, v/v). The PCR product chain 
length was verified by comparison to either DNA molecular weight marker VII or 
VIII. The exact DNA sequence was analysed commercially. 
 
 
6.9 Site-directed mutagenesis 
 
During synthesis of a new DNA strand by polymerases it may occur that the 
sequence differs from the template DNA. To study the activation of these promoter 
constructs by transcription factors it is crucial, especially if the mutation(s) are within 
transcription factors response elements, to mutate the strand back to the wild-type 
template. On the other hand mutations must be inserted into the response elements 
to study DNA protein interactions in EMSAs and to examine potentially changed 
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promoter activity in reporter assays. The QuikChange Site-Directed Mutagenesis Kit 
was used to make the required point mutations. The procedure includes supercoiled 
double-stranded DNA vector with the promoter region of interest and two synthetic 
oligonucleotide primers containing the desired point mutations. The oligonucleotide 
primers, each complementary to opposite strands of the vector, were extended 
during temperature cycling by PfuTurbo DNA polymerase. Due to insertion of the 
oligonucleotide primers a mutated plasmid was generated. After the PCR, the 
product was treated with Dpn I. This endonuclease is specific for methylated and 
hemimethylated DNA and was used to digest the template DNA. E. coli usually 
methylate DNA and therefore the template DNA is susceptible for digestion by Dpn 
I. The remaining vector DNA with the desired point mutations was then cloned into 
XL1-Blue supercompetent cells and the plasmid was analyzed by commercial DNA 
sequencing. 
 
 
6.10 Purification of PCR products 
 
PCR products were extracted from agarose gels with the QIAquick Gel 
Extraction Kit. All centrifugation steps were carried out at 13,000 rpm for 1 min, in a 
microcentrifuge 5417 R. First, the DNA fragment was excised from the agarose gel 
with a scalpel and weighed. Three volumes of buffer QG were added to 1 volume of 
the gel (100 mg ~ 100 µl) and incubated at 50 °C until complete dissolution of the gel 
piece in a thermomixer. The DNA was bound by applying the sample to a QIAquick 
column and centrifugation. The addition of 0.5 ml of buffer QG and centrifugation 
removed all traces of agarose left. The column was washed with 0.75 ml of buffer PE, 
and the DNA was eluted with 100 µl of buffer EB. The DNA was purified and 
precipitated in 100% ethanol with 3 M sodium acetate for at least 30 min at -20 °C, 
followed by centrifugation at full-speed for 10 min, on a microcentrifuge 5417 R. 
After discarding the supernatant, the DNA was washed with 70 % ethanol, 
centrifuged for 5 min and finally dissolved in 15 µl nuclease free water.  
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6.11 Cloning of PCR products into vector systems 
 
PCR products were subcloned into different mammalian vectors depending 
on their function. All PCR products were first ligated with the pGEM-T vector. The 
3’-T overhangs at the insertion site of the vector prevent recirculation and provide 
compatible nucleotides for PCR products synthesised by Taq polymerases which add 
3’-A overhangs to the amplified targets. Synthesised promoter sequences were 
further sublconed in the pGL3 reporter vector containing a coding region for firefly 
luciferase. The pGL3Basic vector was applied to examine factors or promoter 
sequences that potentially regulate mammalian gene expression. All PCR strands 
coding for transcription factors were subcloned into either pcDNA3.1(+) or pSG5 
depending on the restriction enzymes used. In both vectors the expression of the 
subcloned PCR product is under control of the T7 promoter.  
 
 
6.12 Assessment of the transcriptional activities of the promoter regions 
 
The Luciferase Assay System was applied to study the promoter activities. The 
basic principle is that the promoter region of a gene of interest controls the 
expression of a modified coding region for firefly (Photinus pyralis) luciferase. Firefly 
luciferase catalyzes luciferin oxidation to oxyluciferin generating a flash of light. This 
bioluminescent reaction is quantitatively detected by a luminometer (GloMax-Multi+ 
microplate multimode reader or Luminoskan Ascent). Cells were transfected in 48-
well plates at a confluency of 70% with 3 µl FuGENE HD/µg DNA. Cells were co-
transfected with 400 ng pGL3Basic luciferase reporter vectors, 200 ng transcription 
factor expression plasmids and 100 ng control reporter vectors coding for Renilla 
luciferases (Renilla reniformis, pRL-CMV or phRG-tk). 16 hours after the co-
transfections, specific ligands for transcription factors were added if necessary. 36-40 
hours after transfection, cells were harvested in 1x Passive Lysis Buffer for dual 
luciferase assays. The term ‘dual’ refers to the normalization of the activity of the 
experimental reporter to the activity of the internal control minimizing experimental 
variability caused by cell viability or transfection efficiency. The activities of Photinus 
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and Renilla luciferase were sequentially measured from the same 10 µl sample by 
adding 55 µl Luciferase Assay Reagent II followed by 55 µl Stop & Glo Reagent. 
Firefly and Renilla luciferases have dissimilar enzyme structures and substrate 
requirements. These differences allow a selective discrimination between their 
bioluminescent reactions. 
 
 
6.13 RNA interference 
 
Small interfering RNAs (siRNAs) are double-stranded RNA oligonucleotides 
that specifically bind target RNA sequences forming the RNA-induced silencing 
complex (RISC). This complex activates RNases and cleaves RNA, which leads to a 
decreased gene expression. The lipid reagent siLentFect was applied to deliver 
siRNA strands into Caco-2 cells. The reagent is a mixture of a cationic compound and 
a co-lipid. Approximately 500,000 cells/2 ml growth medium were inoculated in 
wells of a 12-well plate the day before transfection. A mixture containing 5 µl 
siLentFect and either 40 nM or 80 nM siRNA, topped up to 100 µl with Opti-Mem 
was incubated for 20 min at room temperature and then added to the cells after 
removal of the growth medium. The cells were then incubated in a CO2/RH -
incubator at 37 °C for 30 min. Following the addition of 500 µl growth medium, the 
plates were incubated during 24 hours in the CO2/RH -incubator. Then, the 
transfection was repeated as described before and possible ligands for transcription 
factors were added. 48 hours after the first transfection, cells were harvested in 
TRIzol for RNA extraction. 
The control group was treated with siGENOME non-targeting siRNA pools.  
 
 
6.14 In vitro translation of transcription factors 
 
The TnT T7 coupled reticulocyte lysate system was used for transcription and 
translation of eukaryotic genes cloned downstream from T7 RNA polymerase 
promoters. The advantage of this kit is the incorporation of the transcription in the 
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translation mix which reduces the expenditure of time and work. Furthermore the 
protein yield is in most cases significantly higher than using standard in vitro rabbit 
reticulocyte lysate-based translations. Typically 1 µg of plasmid DNA was added to 
an aliquot of the TnT master mix and incubated in a 50 µl reaction volume for 90 
minutes at 30 °C. 
 
TnT master mix 
 25 µl TnT lysate 
 2 µl TnT reaction buffer 
 1 µl TnT T7 RNA polymerase 
 0.5 µl Amino acid mixture, minus leucine (1 mM) 
 0.5 µl Amino acid mixture, minus methionine (1 mM) 
 1 µl Rnasin ribonuclease inhibitor (40 U/ µl) 
 
 
6.15 Electrophoretic mobility shift assay 
 
The ability of nuclear protein extracts to specifically bind a DNA sequence was 
examined with electrophoretic mobility shift assays. Oligonucleotides were designed 
to be 27 bases long and had a 5’-AGCT overhang in the top strand and a 5’-GATC 
overhang in the bottom strand. These overhangs made it possible to label the 
annealed oligonucleotides with radioactivity by fill-in reactions in addition to 
sublcone them into the pRL-TK luciferase vector. The oligonucleotides were 
synthesized and purified via Reversed Phase HPLC carried out by Microsynth AG. 
They were dissolved in 10 mM Tris-HCl (pH 8.5) to a concentration of 1 mg/ml 
confirmed by measurement of the absorption. Of each complementary 
oligonucleotide 10 µg were combined, 1 µl of 5 M NaCl was added and made up to 
50 µl with 10 mM Tris-HCl (pH 8.5). The oligonucleotides were then put in a shaking 
thermomixer at 95 °C for 5 min, then at 65 °C for 10 min and at last at 37 °C for 10 
min. After this incubation, 3 µl of 5 M NaCl were added, and the oligonucleotides 
were diluted to a final concentration of 1 µg/µl with 10 mM Tris-HCl (pH 8.5) 
confirmed by absorption measurement. The annealed oligonucleotides (50 ng) were 
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labeled in reactions containing 1 µl of MultiScribe reverse transcriptase (50 U/µl) or 
Superscript II (200 U/µl), 10.5 µl ddH2O, 2 µl 0.1 M DTT, 1 µl 5 mM 
dGTP/dCTP/dTTP, 1 µl α-32P-dATP solution (20 mCi/ml, 6000 Ci/mmol) and the 
reverse transcriptase specific buffer to a final volume of 20 µl. These reaction 
mixtures were incubated at 37 °C for 30 min, 30 µl of ddH2O were added and applied 
to MicroSpin G-25 columns to remove unincorporated nucleotides. They were spun 
down at 750 x g for 2 min, and the labeled probes were collected. Ten µg of nuclear 
cell extracts prepared using the NE-PER extraction kit, or 1.5 µl of in vitro translated 
transcription factor proteins generated with the TnT T7 coupled reticulocyte lysate 
system were used per DNA-binding reaction. Protein-DNA complexes were formed 
in the binding buffer (20 mM Tris-HCl pH 8.0, 60 mM KCl, 2 mM MgCl2, 12% (v/v) 
glycerol, 0.3 mM DTT, 87.5 ng/µl preboiled poly(dI-dC)-poly(dI-dC)) in a total 
volume of 20 µl. 50,000 cpm of the labeled probe were added to the reaction and 
incubated for 10 min at 30 °C. In supershift experiments, 1 µl of the corresponding 
antibody was added to the reaction 1 h before the labeled probe and incubated at 4 
°C. The samples were loaded onto pre-electrophoresed 5% native acrylamide gels 
(per gel: 6.25 ml 40% acrylamide, 4.1 ml 2% bisacrylamide, 2.5 ml 10x TBE, 500 µl 
10% APS, 50 µl TEMED, 36.6 ml ddH2O) and run at 200 V in 0.5x diluted TBE buffer 
for approximately 3 hours. The gels were then fixed in 10% (v/v) acetic acid for 10 
min, rinsed with water, dried onto Whatman DE81 paper under vacuum, and 
exposed to Kodak BioMax MR-1 films at -80°C. 
 
 
6.16 Extraction of nuclear and cytoplasmic proteins 
 
The extraction of nuclear and cytoplasmic proteins from cultured cells was 
achieved by use of the NE-PER Nuclear and Cytoplasmic extraction kit. The stepwise 
process involves lysis of the cells, separation of the cytoplasm from the intact nuclei 
and extraction of the proteins from the DNA and RNA of the nuclei. The following 
steps refer to extract the proteins from cells cultivated in a 10-cm Corning dish. Cells 
were washed with 5 ml PBS and scraped into 1 ml ice-cold PBS containing 1x 
Complete solution. After a spin at 700 x rcf at 4 °C for 2 min  (microcentrifuge 5417 R) 
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and removal of the supernatant, 150 µl cytoplasmic extraction reagent I (CER I 
containing 1x Complete solution) was added and the tube was vortexed for 5 s. The 
addition of the cytoplasmic extraction reagent II (CER II) was followed by 5 s 
vortexing, 2 min incubation on ice and again 5 s vortexing. The sample was 
centrifuged for 4 min at 14,000 x rcf at 4 °C, (microcentrifuge 5417 R). The 
supernatant containing the cytoplasmic proteins was transferred to a new tube and 
stored. The remaining pellet was resuspended in 25 µl nuclear extraction reagent 
(NER) containing 1x Complete solution, vortexed for 5 s, incubated on ice for 20 min 
and vortexed again for 5 s. Following a centrifugation at maximum speed for 10 min 
at 4 °C and transfer of the supernatant nuclear extract to a new tube, a second nuclear 
extraction with NER was performed as described above and both nuclear extracts 
were combined. The protein concentration of all samples was determined with an 
assay based on the use of bicinchoninic acid. 
 
 
6.17 BCA protein assay 
 
Protein concentrations were determined by spectrophotometric detection 
based on bicinchoninic acid (BCA) using the BCA protein assay kit. The method 
combines the reduction of Cu2+ to Cu1+ by proteins in an alkaline medium (Biuret 
reaction) with the spectrophotometric detection of Cu1+ using a reagent containing 
BCA. The complex of two BCAs and one Cu1+ ion shows a strong absorbance at 562 
nm. All protein concentrations were determined with reference to bovine γ-
globuline. A series of bovine γ-globuline concentrations ranging from 0.025 mg/ml 
to 1 mg/ml were assayed before the concentration of each unknown was determined 
based on the standard curve. Nuclear extract concentrations were determined in 2 µl 
or 4 µl sample volumes, whereas the protein determination in transport experiments 
was performed with 12.5 µl of lysates from 35-mm dishes. All samples were 
equalized with regard to the buffers used in nuclear extracts or transport 
experiments to a total volume of 50 µl. Two hundred µl of the working reagent 
containing the BCA reagent A and reagent B (50:1, v/v) was added and incubated at 
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37 °C for 30 min. The absorption at 550 nm was measured with a spectrophotometer 
(GloMax-Multi+ microplate multimode reader). 
 
 
6.18 Western blot 
 
To detect specific proteins in a RIPA buffer extract of cultivated cells, gel 
electrophoresis was applied. After removing the secondary or tertiary structures with 
reducing agents, the proteins of a sample were separated by their molecular weight. 
The separating gel was prepared by mixing 4.4 ml ddH2O, 2.5 ml resolving gel 
buffer, 3 ml 30% acrylamide/bis solution, 100 µl 10% APS and 5 µl TEMED. The 
stacking gel consisted of 3.05 ml ddH2O, 1.25 ml stacking buffer, 650 µl 30% 
acrylamide/bis solution, 50 µl 10% APS and 7 µl TEMED. 10 well-combs and 0.75 
mm spacers were used in all experiments. Fifteen µg of cell extract were adjusted to a 
volume of 10 µl with PBS 1x. After addition of 2.5 µl loading buffer, the mix was 
heated for 10 minutes at 85 °C, spun down and applied into the wells. As protein 
standard 7 µl of SeeBlue Plus2 were loaded onto the gel. The gel was run first at 300 
V for 5 min, then 150 V until the probes reached the separating gel and finally at 200 
V. Afterwards the protein was transferred onto a nitrocellulose membrane as 
following: First, fresh transfer buffer was prepared (3 g TRIZma-base, 14.4 g glycine, 
200 ml methanol and ddH2O to give a final volume of 1 l). The gel was placed on top 
of the membrane and sandwiched between two stacks of sponges and filter papers. 
After placing in a tank an ice-cold block was put into the tank to keep the transfer 
buffer cool. A current of ~250 mA during 1 hour was used to pull the proteins from 
the gel into the nitrocellulose membrane. The blot was washed with blocking 
solution (PBS 1x, 5% non fat dry milk, 0.1% Tween 20) by incubation of 1 hour 
shaking at RT. The incubation with the first antibody varied in time and 
concentration (more precisely described in the result section). The blot was washed 3 
times for 15 minutes with plenty of block solution. The secondary HRP-conjugated 
antibody incubation varied as well in time and concentration (more precisely 
described in the result section). The blot was briefly dried and covered with 
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SuperSignal WestFemto for 5 minutes. The blot was again briefly dried, covered with 
plastic wrap and exposed to Amersham Hyperfilm ECL (the exposure time varied). 
 
 
6.19 Chromatin immunoprecipitation (ChIP) 
 
Chromatin immunoprecipitation is a technique which allows to determine 
whether specific proteins interact with genomic regions. The basis of this technique is 
to fix chromatin proteins to DNA by treating cells with formaldehyde. The chromatin 
is then extracted, sheared by sonication into fragments and the proteins associated 
with DNA are immunoprecipitated with antibodies. The following instructions 
always refer to a ChIP starting with a 10-cm dish using the ChIP-IT express 
chromatin immunoprecipitation kit.  
 
6.19.1 Cell fixation 
 
The following solutions were freshly prepared: 
1. Fixation solution: 0.45 ml 16% (v/v) formaldehyde to 7 ml minimal cell 
culture medium, placed at RT 
2. 1x PBS: add 0.84 ml 10x PBS to 7.6 ml ddH2O, placed on ice 
3. Glycine Stop Fix solution: combine 361 µl 10x Glycine buffer, 361 µl 10x 
PBS and 2.9 ml ddH2O, placed at RT 
4. Cell Scraping Solution: add 72 µl 10x PBS to 650 µl ddH2O, placed on ice. 
Just before use 3.6 µl 100 mM PMSF were added 
After removal of the growth medium, the cells were fixed with the fixation 
solution on a shaking platform during 10 min. The fixation solution was sucked off 
and the cells were washed with 1x PBS solution. The fixation reaction was then 
stopped by adding the Glycine Stop Fix solution rocking for 5 min. The cells were 
again washed with 1x PBS solution after pouring off the Glycine Stop Fix solution. 
The cells were scraped into the Cell Scraping Solution and transferred to a tube. The 
cells were centrifuged (2,500 rpm, 10 min, 4 °C, microcentrifuge 5417 R) and the 
supernatant was removed. 
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6.19.2 Shearing by sonication 
 
The pellet was resuspended in 1 ml ice-cold Lysis Buffer supplemented with 5 
µl PIC and PMSF and incubated for 30 min on ice. The cells were transferred to an 
ice-cold dounce homogenizer and the nuclei were released with 10 strokes. The 
suspensions were pipetted into 1.7-ml siliconized tubes and centrifuged (5,000 rpm, 
10 min, 4 °C) to pellet the nuclei. The supernatant was discarded and the nuclei 
resuspended in 350 µl Shearing Buffer supplemented with 1.75 µl PIC and placed on 
ice. The DNA was sheared with the Branson Digital sonifier at power setting 25% 
with a pause of 30 s between each pulse: The nuclei from Caco-2 were sonified with 5 
pulses, whereas Huh7 needed 10 pulses. The sheared chromatin was centrifuged 
(15,000 rpm, 10 min, 4 °C, microcentrifuge 5417 R). The supernatant was transferred 
to a new 1.7-ml siliconized tube. 15 µl from each sample was aliquoted as the ‘input 
DNA’. 
 
6.19.3 Immunoprecipitation 
 
For the precipitation step, 50 µl aliquots of sheared chromatin were incubated 
without any antibody, with 1 µg of negative control anti-serum mouse IgG1 or with 1 
µg of the antibodies raised against the transcription factors of interest. Twenty five µl 
of protein G magnetic beads, 10 µl ChIP buffer and 1 µl PIC were added to the 
reaction mixture and ddH2O was added to a final volume of 100 µl. The reaction 
mixtures were incubated on an end-to-end rotator at 4 °C overnight. 
 
6.19.4 Wash of the magnetic beads 
 
The tubes were placed on a magnetic stand and the supernatants carefully 
removed. The beads were then washed 1x with 800 µl ChIP buffer I and 2x with 800 
µl ChIP buffer II. After the washing, as much supernatant as possible was removed. 
 
 
34 
 
 
6.19.5 Elution of chromatin, reversion of cross-links and treatment with proteinase K 
 
The beads were resuspended with 50 µl elution buffer AM2 and incubated for 
15 min in a thermomixer at RT. To elute the chromatin, 50 µl of the reverse cross-
linking buffer was added. The tubes were placed in a magnetic stand and the 
supernatant containing the chromatin was transferred to fresh tubes. To 10 µl of the 
‘input DNA’ sample, 88 µl ChIP buffer 2 and 2 µl 5 M NaCl were added. The ChIP 
and the ‘input DNA’ samples were heated at 95 °C for 15 min, cooled down to RT 
and supplemented with 2 µl proteinase K. The samples were digested at 37 °C during 
1 h followed by addition of 2 µl proteinase K stop solution. Two amplicons were 
assayed by immunoprecipitation tests, using puReTaq Ready-To-Go pcr beads and 
the oligonucleotides of interest. Oligonucleotides were designed to amplify the 
transcription factor DNA response element. As negative control served 
oligonucleotides amplifying a region from an intron of the gene of interest. 
After the initial denaturation stage at 94 °C for 3 min, the PCR cycling conditions 
were 94 °C for 20 s, 60 °C for 30 s, and 72 °C for 1 min. Samples were taken from the 
30th,  35th or 40th cycle. 5 µl of each PCR product were resolved on 1.5% agarose gels 
and detected with SYBR - Safe DNA gel or GelRed stain. 
 
 
6.20 Reverse transcription of RNA 
 
The High Capacity cDNA Reverse Transcription kit was used for reverse 
transcription of total RNA to single-stranded cDNA. Between 1 and 2 µg of RNA 
were reverse transcribed in 20 µl reaction volumes. Two µl of 10x RT buffer, 0.8 µl of 
25x dNTP mix, 2 µl 10x RT random primers, 1 µl MultiScribe reverse transcriptase, 1 
µl RNase inhibitor and 3.2 µl of ddH2O were combined with the respective amount of 
RNA in 10 µl ddH2O and incubated in a thermomixer as follows: 10 min at 25 °C, 120 
min at 37 °C and 5 min at 85 °C. 
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6.21 Ex vivo treatment of rodent tissue specimens with ligands of transcription 
factors 
 
Tissue samples of rodents were collected just after euthanasia and placed 
immediately in ice-cold PBS. Small tissue pieces were placed into pre-warmed 
DMEM supplemented with agonists or antagonists of transcription factors of 
interest. The samples were incubated during 4 hours in a CO2/RH incubator at 37 °C. 
The RNA of the samples was isolated following the protocol ‘RNA extraction’.  
 
 
6.22 Statistical analysis 
 
All cell-based experiments were repeated at least three times (except the co-
transfection assays of the mSlco1a1 and mSlco1a4 promoter constructs, which were 
done only once). In the present thesis representative experiments are shown. All data 
from luciferase assays and real-time PCR measurements were analysed as means ± 
SDs. The values of each experimental group were analysed by one-way analysis of 
variance (ANOVA) followed by the Tukey post hoc test. P values < 0.05 were 
considered as significant. The statistical values were calculated based on the software 
GraphPad Prism. 
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6.23 List of chemicals / kits / equipment 
 
α-32P-dATP (20 mCi/ml, 6000 Ci/mmol) (PerkinElmer, Waltham MA, USA) 
40% acrylamide (Bio-Rad, Hercules CA, USA) 
30% acrylamide/bis solution (Bio-Rad, Hercules CA, USA) 
2% bisacrylamide (Bio-Rad, Hercules CA, USA) 
9-cis-RA (10 mM in DMSO) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
6-/ 12-/ 24-/ 48-well Corning multiple well plates (Corning, Corning NY, USA) 
100 mm Corning dishes (Corning, Corning NY, USA) 
15-deoxy-Δ12,14-prostaglandin J2 (10 mM in DMSO) (Sigma-Aldrich, Saint-Louis,             
Missouri MO, USA) 
7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, California CA, 
USA) 
18G x 1 ½ ‘‘, 21G x 1 ½ ‘‘, and 22G x 1 ¼ ‘‘ needles (Terumo, Tokyo, Japan) 
1.5 ml RNase-free Microfuge tubes (Ambion/ Applied Biosystems, Foster City, 
California CA, USA) 
1.5 ml Safe-Lock tubes (Vaudaux-Eppendorf , Hamburg, Germany) 
1 ml U-100 syringes (Nipro, Osaka, Japan) 
Advantage-GC 2 PCR (Clontech Laboratories/ Takara Holding Company Inc, Kyoto, 
Japan) 
Agarose for routine use (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
AHPN (10 mM in DMSO) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Amersham Hyperfilm ECL (GE Healthcare, Fairfield CT, USA) 
Anti-serum mouse IgG1 (Dako Denmark A/S, Glostrup, Denmark) 
APS ammonium persulfate (10% w/v) (Sigma-Aldrich, Saint-Louis, Missouri MO, 
USA) 
Avanti J-E Centrifuge (Beckman Coulter, Brea, California CA, USA) 
BCA protein assay kit (Thermo Fisher Scientific, Waltham MA, USA) 
Bovine γ-globuline (Bio-Rad, Hercules CA, USA) 
Branson Digital sonifier (Branson, Ultrasonics, Danbury CT, USA) 
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Carbenicillin (stock 50 mg/ml; final concentration 50 µg/ml) (Novagen/ Merck, 
Whitehouse Station, New Jersey NJ, USA) 
CDCA (100 mM in DMSO) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Centrifuge 5810 R (Vaudaux-Eppendorf AG, Hamburg, Germany) 
ChIP-IT express chromatin immunoprecipitation kit (Active Motif, Carlsbad, 
California CA, USA) 
Ciprofibrate (30 mM in DMSO) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Complete, Mini protease inhibitor cocktail tablets (Hoffmann-La Roche, Basel, 
Switzerland) 
CryoTube vials (Nunc, Roskilde, Denmark) 
Dexamethasone (1 mM in EtOH) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
DNA molecular weight marker VII and VIII (Hoffmann-La Roche, Basel, 
Switzerland) 
Escherichia coli (Life Technologies, Carlsbad CA, USA and unknown origin) 
Ethanol for molecular biology, assay: ≥ 99.8% (Sigma-Aldrich, Saint-Louis, Missouri 
MO, USA) 
Fetal bovine serum gold (PAA Laboratories, Pasching. Austria) 
Formaldehyde (Thermo Fisher Scientific, Waltham MA, USA) 
FuGENE HD (Hoffmann-La Roche, Basel, Switzerland) 
GelRed stain (Chemie Brunschwig, Basel, Switzerland) 
GeneJET Plasmid Miniprep Kit (Fermentas/ Thermo Fisher Scientific, Waltham MA, 
USA) 
GloMax-Multi+ microplate multimode reader (Promega, Madison WI, USA) 
Glycine (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
GraphPad Prism software (GraphPad, San Diego CA, USA) 
GW-9662 (100 mM in DMSO) (Enzo Biochem, Farmingdale NY, USA) 
GW-1929 (40 mM in DMSO) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
High Capacity cDNA Reverse Transcription (Invitrogen, Carlsbad, California CA, 
USA) 
Hyperforin (0.25mg/ml) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
illustra MicroSpin G-25 columns (GE Healthcare, Fairfield CT, USA) 
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illustra puReTaq Ready-To-Go pcr beads (GE Healthcare, Little Chalfont, United 
Kingdom) 
Isopropanol for molecular biology, assay ≥ 99% (Sigma-Aldrich, Saint-Louis, 
Missouri MO, USA) 
Formaldehyde 16% (Thermo Fisher Scientific, Waltham MA, USA) 
Kodak BioMax MR-1 (PerkinElmer, Waltham MA, USA) 
LB agar (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
LB broth EZMix (Sigma-Aldrich, Saint-Louis, Missouri MO, USA 
Loading buffer: 95 µl 5 x see blue and 5 µl β-mercaptoethanol 
Luciferase Assay System (Promega, Madison WI, USA) 
Luminoskan Ascent (Thermo Fisher Scientific, Waltham MA, USA) 
Methanol (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Microcentrifuge 5417 R (Vaudaux-Eppendorf AG, Hamburg, Germany) 
Mifepristone (50 mM in EtOH) (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
MK-886 (40mM in DMSO) (Enzo Biochem, Farmingdale NY, USA) 
NE-PER nuclear and cytoplasmatic extraction kit (Thermo Fisher Scientific, Waltham 
MA, USA) 
Nitrocellulose membrane (Bio-Rad, Hercules CA, USA) 
Non-fat dry milk (Bio-Rad, Hercules CA, USA) 
Nuclease-free water (Thermo Fisher Scientific, Waltham MA, USA) 
Opti-Mem reduced serum media (Invitrogen, Carlsbad, California CA, USA) 
PBS (Invitrogen, Carlsbad, California CA, USA) 
PCN (2.6 mM in EtOH) (unknown origin) 
Penicillin/ streptomycin in 0.85% saline (Gibco/ Invitrogen, Carlsbad, California CA, 
USA) 
poly(dI-dC)-poly(dI-dC) acid sodium salt (Sigma-Aldrich, Saint-Louis, Missouri MO, 
USA) 
Qiagen Plasmid Midi Kit (Qiagen, Hilden, Germany) 
QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) 
QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, California CA, USA) 
Resolving gel buffer (Bio-Rad, Hercules CA, USA) 
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See-Blue Plus2 pre-stained protein standard (Invitrogen, Carlsbad, California CA, 
USA) 
siGENOME non-targeting siRNA pool (Thermo Fisher Scientific, Waltham MA, 
USA) 
siLentFect (Bio-Rad, Hercules CA, USA) 
Sodium acetate solution pH 5.0 (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Spectrophotometer ND-1000 (NanoDrop, Wilmington DE, USA) 
Stacking gel buffer (Bio-Rad, Hercules CA, USA) 
SuperSignal WestFemto (Thermo Fisher Scientific, Waltham MA, USA) 
SYBR - Safe DNA gel stain (Invitrogen, Carlsbad, California CA, USA) 
TBE buffer 10x (Thermo Fisher Scientific, Waltham MA, USA) 
TEMED N,N,N',N'-Tetramethylethylendiamin (Merck, Darmstadt, Germany) 
Thermomixer comfort (Vaudaux-Eppendorf , Hamburg, Germany) 
TipOne filter tips (10 µl, 20 µl, 200 µl, 1000 µl) (Starlab, Brussels, Belgium) 
TnT T7 coupled reticulocyte lysate system (Promega, Madison WI, USA) 
TRIZma (Sigma-Aldrich, Saint-Louis, Missouri MO, USA) 
Tris-EDTA buffer solution pH 7.4 (Fluka/ Sigma-Aldrich, Saint-Louis, Missouri MO, 
USA) 
TRIzol (Invitrogen, Carlsbad, California CA, USA) 
Troglitazone (30 mM in DMSO) (Enzo Biochem, Farmingdale NY, USA) 
Tween 20 (Merck, Whitehouse Station, New Jersey NJ, USA) 
Whatman DE81 paper (GE Healthcare, Fairfield CT, USA) 
WY-14643 (100 mM in DMSO) (Merck KgaA, Darmstadt, Germany) 
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7 Results 
 
7.1 The peptide transporter 1 (PEPT1) 
 
All methodologies applied in this study are listed and described in the section 
Materials and Methods. 
 
7.1.1 In silico identification of putative PPAR response elements in human and 
rodent PEPT1/Pept1 promoters 
 
The peptide transporter PEPT1 mediates the uptake of di-/tri-peptides and 
peptidomimetic drugs in the small intestine. PEPT1 is also aberrantly expressed in 
the colon of patients suffering from inflammatory bowel disease (IBD) (Merlin et al., 
2001). In addition the peroxisome proliferator-activated receptor γ (PPARγ), a ligand-
dependent transcription factor, plays an important role in IBD etiology. As the ability 
of PPARγ to regulate human/rodent PEPT1/Pept1 genes remained unelucidated, 
PEPT1/Pept1 promoter activities were studied in intestine-derived human and 
rodent cell lines. 
In silico analysis of human and rodent PEPT1/Pept1 promoters revealed 
several putative peroxisome proliferator-activated receptor response elements 
(PPARs) within around 5000 base pairs towards the 5’-end of the promoter (NCBI 
accession numbers: NW_925517, human promoter; NW_001030563, mouse promoter; 
NW_001084709, rat promoter). Two web-based programs, MatInspector 
(www.genomatix.de) and NUBIScan (www.nubiscan.unibas.ch), identified several 
putative PPAR response elements (PPREs). Especially focused on PPREs close to the 
transcriptional start site, two human, four mouse and one rat PPRE were identified. 
To examine the functionality of the PPREs, promoter constructs of different lengths 
were cloned into the reporter assay vector pGL3Basic. Three human promoter 
constructs containing PPREs (PEPT1 -2010/+57, PEPT1 -1288/+57, PEPT1 -506/+57) 
and one without any PPRE (PEPT1 -65/+57) were used for co-transfections and 
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EMSAs. One construct covering the PPREs (mPept1 -2150/+6, rPept1 -1943/+20) and 
one without any PPREs (mPept1 -1095/+6, rPept1 -1048/+20) were cloned from the 
rodent Pept1 promoters (Fig. 1). 
 
 
 
 
 
Fig. 1: Human and rodent PEPT1/Pept1 promoter sequences and constructs. The parts 
of the promoters cloned into luciferase reporter vectors are indicated by their 
terminal nucleotides. The 5’-end and the 3’-end of the cloned constructs are indicated 
with -/+ in relation to the start of transcription. The longest shown human or rodent 
promoter sequences represent the respective templates used to clone the constructs. 
Yellow boxes: PPREs, green boxes: start of translation (ATG).  
 
The PPARs bind as heterodimers with the retinoid X receptor alpha (RXRα) to 
the DNA (PPAR:RXRα). In mammalians, the preferred consensus DNA response 
element is a direct repeat of two hexanucleotides spaced by one nucleotide, 
AGGTCAnAGGTCA (Kliewer et al., 1992) (Fig. 2). The potential PPRE in the human 
and rodent PEPT1/Pept1 promoters are listed in Figure 2. 
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PPAR:RXRα consensus:  A G G T C A n A G G T C A 
 
PEPT1 wt -389/-401:  G G G A C A g T G G T C A 
 
PEPT1 wt -1500/-1512:           T G G G C A a A G G A T A 
 
 
mPept1 wt -1283/-1295:  T T A C C C t T G A A C T 
 
mPept1 wt -1762/-1774:  T G T T C T g T G T C C T 
 
mPept1 wt -1828/-1840:  T G T C C T c T A C A C T 
 
mPept1 wt -1862/-1874:  T C T T C T t T G A C C T 
 
 
rPept1 wt -1475/-1487:           T G A A C T t T G T G C T 
 
 
Fig. 2: Identification of putative PPREs within the human and rodent PEPT1/Pept1 
promoters. Identical nucleotides compared to the PPAR:RXRα consensus sequence 
are shown in bold letters. The location of the PPREs is indicated relative to the 
transcriptional start site. 
 
 
7.1.2 Transactivation of the human and rat PEPT1/Pept1 promoters by PPARα 
and PPARγ 
 
Different human and rodent promoter constructs were used to study whether 
the contained PPREs mediate the PPAR:RXRα-dependent activation in Caco-2 cells. 
Final concentrations of 30 µM ciprofibrate, 10 µM 15-deoxy-Δ12,14-prostaglandin J2 
(15d-PGJ2), and 1 µM 9-cis-retinoic acid (9-cis-RA) were used as agonists for PPARα, 
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PPARγ and RXRα receptor proteins, respectively. Two human PEPT1 promoter 
constructs covering one PPRE and a human PEPT1 promoter part without a putative 
PPRE were transiently transfected. The two mouse promoter constructs covered four 
or no PPRE. The rat promoter was examined with two promoter constructs 
containing a PPRE and one construct lacking the putative PPRE. 
Both PEPT1 (-506/+57) and PEPT1 (-1288/+57) promoter fragments were potently 
activated by PPARγ: RXRα, but not PPARα: RXRα. The short PEPT1 (-65/+57) 
construct did not mediate a significant luciferase activity by both PPARα:RXRα and 
PPARγ:RXRα. The mPept1(-2150/+6) construct was not transactivated by either 
heterodimer in contrast to the weak activation of mPept1(-1095/+6) by PPARγ:RXRα. 
The two rat promoter fragments were both significantly (p < 0.001) activated by 
PPARγ:RXRα but not by PPARα:RXRα (Fig. 3).  
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Fig. 3: Co-transfections of Caco-2 cells with PEPT1/Pept1 promoter constructs  
and PPARα, PPARγ and RXRα expressing plasmids.. Caco-2 cells were co-
transfected with reporter-linked human and rodent PEPT1/Pept1 promoter 
constructs (nucleotide numbering relative to the transcription start site), expression 
plasmids coding for RXRα, PPARα and PPARγ and their respective ligands 9-cis-RA, 
ciprofibrate and 15d-PGJ2. The relative luciferase activities are shown relative to the 
cells transfected with pSG5 and pcDNA3.1(+) (white bars). Blue bars represent the 
relative luciferase activities of cells co-transfected with pSG5- PPARα and pCMX- 
RXRα, whereas green bars represent co-transfections with pSG5- PPARγ and pCMX-
RXRα. ***, p < 0.001, *, p < 0.1, n.s., not significant. 
 
 
7.1.3 Binding of in vitro translated PPARγ proteins to human and rat PPREs 
 
To study the potential interaction of PPARγ and RXRα with the human and 
rodent PPREs in vitro, electromobility shift assays (EMSAs) were performed. 
Oligonucleotides comprising the wild-type human and rodent PPAR binding sites 
were synthesised and radio-labelled. The mammalian expression vector pSG5, pSG5-
PPARγ and pCMX-RXRα were in vitro translated with the TnT T7 coupled 
reticulocyte lysate system. Radiolabeled wild-type PPREs were incubated with the 
proteins and the complexes formed are shown in figure 4. The interaction of PPRE 
PEPT1 wt -1500/-1512 and PPARγ:RXRα was stronger than the binding of PEPT1 wt 
-389/-401 to the heterodimer. None of the mouse PPREs was able to bind the protein 
heterodimers. The rat PPRE showed the strongest interaction between the DNA and 
PPARγ:RXRα. As a positive control, the interaction of the known PPRE of the human 
45 
 
apical sodium-dependent bile acid transporter ASBT and PPARγ:RXRα was used 
(Jung et al., 2002). 
 
 
 
Fig. 4: Electromobility shift assays to show the specific binding of in vitro translated 
PPARγ proteins to human and rat PPREs. EMSAs were performed with in vitro 
translated PPARγ proteins and the PEPT1/Pept1 promoter sequences containing the 
wild-type PPARγ consensus binding motif as radiolabelled probes. The numbering 
of the human and rodent PPREs is relative to the transcription start site. 
 
 
7.1.4. PEPT1/Pept1 promoter constructs featuring wild-type and mutated PPRE 
transactivation by PPARγ:RXRα 
 
To reduce the binding of PPARγ:RXRα, site-directed mutagenesis of all 
predicted human and rat PPREs was applied. The preferred DNA sequence for 
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PPARγ:RXRα binding was examined by Okuno and co-workers (2001) with PCR-
mediated random site selection. The nucleotides to be mutated were chosen 
according to their studies. The wild-type PPREs were mutated as following with the 
site-directed mutagenesis kit and further cloned into the reporter vector pGL3Basic 
(mutated oligonucleotides are red labelled): 
 
   PEPT1 wt -389/-401: GGGACAgTGGTCA   
    mut: GTGACGGTTGGCA 
 
 PEPT1 wt -1500/-1512: TGGGCAaAGGATA 
     mut: TAGGCCAAAAATA 
 
 rPept1 wt -1475/-1487: TGAACTtTGTGCT 
            mut:   TGCAATTCGTGAT 
 
 
 
Three human PEPT1 promoter constructs with either one or two mutated 
PPREs and the rat Pept1 promoter with the mutated PPRE were transiently 
transfected into Caco-2 cells. The activity of the mutated human promoters was 
compared to a longer construct of the human PEPT1 promoter than in figure 3. The 
same final concentrations of 10 µM 15d-PGJ2, and 1 µM 9-cis-RA were used as 
agonists for the nuclear receptors PPARγ and RXRα. The human wild-type PEPT1 
promoter and the three human PEPT1 constructs with mutated PPREs were activated 
significantly by PPARγ:RXRα. In contrast to the mutated form the wildtype rat Pept1 
promoter construct was not transactivated (Fig. 5). 
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Fig. 5: Caco-2 cells co-transfected with reporter-linked human and rodent 
PEPT1/Pept1 promoter constructs (nucleotide numbering relative to the transcription 
start site) with either wild-type or mutated PPREs. The expression plasmids 
featuring RXRα and PPARγ constructs and their respective ligands 9-cis-RA and 
prostaglandin J2 were added as described above. The relative luciferase activities are 
shown relative to the cells transfected with pSG5 and pcDNA3.1(+) (white bars). Blue 
bars represent the relative luciferase activities of cells co-transfected with pSG5 and 
pCMX-RXRα, grey bars represent co-transfections with pSG5-PPARγ and pCMX-
RXRα and green bars show the relative luciferase activities of cells co-transfected 
with pSG5-PPARγ and pSG5. ***, p < 0.001, n.s., not significant. 
 
 
 
 
 
48 
 
7.1.5 Relative PEPT1 mRNA quantification with real-time PCR in human cell 
lines 
 
To study the relevance of PPARγ:RXRα in the regulation of the intestinal 
PEPT1 expression, in vivo relative mRNA levels of 5 human colon derived cell lines 
were measured with real-time PCR. The expression level in HT-29 cells was set to 1 
and all other cell lines were compared relative to this. The cycle threshold (Ct) of 
PEPT1 was always normalized to the Ct of the housekeeping gene beta-actin in all 
cell lines. In Caco-2 cells, the Ct for PEPT1 was 25 and in T84 cells 32. In all other cell 
lines the Ct values were above 35 (Fig. 6).  
 
 
Fig. 6: Endogenous PEPT1 mRNA expression in human cell lines. The PEPT1 mRNA 
expression levels of Caco-2, DLD-1, T84 and LS174T cells are shown relative to the 
PEPT1 mRNA of HT-29. The PEPT1 mRNA expression levels were normalized for 
beta-actin. 
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7.1.6 Relative PPARα, PPARγ and RXRα mRNA quantification with real-time 
PCR in human cell lines 
 
The applicability of the 5 cell lines to study the interaction between PEPT1, 
PPARα, PPARγ and RXRα was further examined by measuring the relative mRNA 
levels of the three transcription factors with real-time PCR. The expression level in 
HT-29 cells was set to 1 and all other cell lines were compared relative to this. The 
cycle thresholds of PPARα, PPARγ and RXRα of all cell lines were normalized to the 
cycle thresholds of the housekeeping gene beta-actin. The highest levels of PPARα 
were found in T84 and LS174T cells (Fig. 7A). Caco-2 and DLD-1 cells had similar 
expression levels as HT-29. PPARγ had significantly higher mRNA levels in T84 
cells. All other cell lines had lower mRNA levels than HT-29 (Fig. 7B). RXRα was 
similar or lower expressed in all cell lines compared to HT-29 (Fig. 7C). 
 
A       B 
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Fig. 7 A-C: Endogenous PPARα, PPARγ and RXRα mRNA expression in human cell 
lines. The mRNA expression level of a gene of interest was always set in relation to 
that obtained for HT-29. The mRNA expression levels were normalized to the beta-
actin mRNA expression levels of the probes. ***, p < 0.001, n.s., not significant. 
 
 
7.1.7 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
upon treatment with ligands for 48 hours in normal growth medium 
 
The ability of the protein heterodimer PPARγ:RXRα to activate the PEPT1 
promoter within living cells was examined by adding different ligands to the Caco-2 
growth medium. 9-cis-RA, a natural RXRα agonist, the endogenous agonist 15d-PGJ2 
of PPARγ and a synthetic antagonist of PPARγ, GW-9662, were added to the growth 
medium of Caco-2 cells. After a 48-hour incubation period, the relative mRNA levels 
of PEPT1 were measured with real-time PCR. The Ct of PEPT1 was normalized to the 
Ct of the housekeeping gene beta-actin.The addition of either 9-cis-RA, 15d-PGJ2 and 
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GW-9662 or the combination of 15d-PGJ2/GW9662 resulted in no elevated PEPT1 
mRNA expression compared to the control cells only treated with the solvent of the 
ligands. A slightly lower expression level was observed when the cells were treated 
with 15d-PGJ2 combined with 9-cis-RA (Fig. 8). 
 
 
 
Fig. 8: PEPT1 mRNA expression of Caco-2 cells after 48 hours treatment with 
different ligands of PPARγ and RXRα in the growth medium. The natural ligands of 
PPARγ and RXRα, P15d-PGJ2 and 9-cis-RA and the synthetic antagonist of PPARγ, 
GW-9662, were added either separately or in combination. There were no significant 
alterations in the PEPT1 mRNA expression compared to the control. 
 
 
7.1.8 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
treated with ligands for 48 hours in delipidated growth medium 
 
Fetal bovine serum which is added to the growth medium of most cell lines 
contains free fatty acids. These are natural agonists of PPARγ. To avoid the 
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interference of the added ligands with the free fatty acids of the growth medium, 
experiments were conducted with delipidated fetal calf serum. The same ligands, 
incubation period and normalization procedure as used for the previous experiment 
were applied to investigate any effect on mRNA levels of PEPT1. The combined 
addition of 15d-PGJ2 and 9-cis-RA resulted in lower PEPT1 mRNA expression level 
that showed low significance. The other ligands did not change the mRNA levels 
compared to the control (Fig. 9). 
 
 
 
Fig. 9: PEPT1 mRNA expression of Caco-2 cells after 48 hours treatment with 
different ligands of PPARγ and RXRα in delipidated growth medium. The natural 
ligands of PPARγ and RXRα, 15d-PGJ2 and 9-cis-RA and the synthetic antagonist of 
PPARγ, GW-9662, were added either separately or in combination.  
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7.1.9 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
treated for 24 hours in normal growth medium 
 
The same ligands as in the previous experiments were used with a 24-hours 
incubation period to investigate potentially altered PEPT1 mRNA levels in Caco-2 
cells. The expression levels of PEPT1 mRNA were normalized to those of beta-
actin.The addition of 15d-PGJ2 and 15d-PGJ2/GW-9662 resulted in higher but not 
significant PEPT1 mRNA levels. 9-cis-RA, GW-9662 and PGJ2/9-cis-RA did not 
increase the expression of PEPT1 mRNA (Fig. 10). 
 
 
 
Fig. 10: PEPT1 mRNA expression in Caco-2 cells after 24 hours treatment with 
different ligands of transcription factors in normal growth medium. The natural 
ligands of PPARγ and RXRα, 15d-PGJ2 and 9-cis-RA, and the synthetic antagonist of 
PPARγ, GW-9662, were added either separately or in combination.  
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7.1.10 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
treated for 24 hours in delipidated growth medium 
 
The same experimental design as described in Figure 10 was also carried out 
with delipidated growth medium and a 24 hours incubation period. GW-9662 
increased the PEPT1 mRNA expression significantly, whereas the other ligands had 
no significant effect on the endogenous PEPT1 mRNA expression (Fig. 11).  
 
 
 
Fig. 11: PEPT1 mRNA expression in Caco-2 cells after 24 hours treatment with 
different ligands of transcription factors in delipidated growth medium. *, p < 0.1, 
n.s., not significant. 
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7.1.11 Relative RXRα, PPARα and PPARγ mRNA quantification with real-time 
PCR in Caco-2 cells treated with siRNA inhibiting the expression of RXRα, PPARα 
and PPARγ 
 
Knockdown experiments were performed to investigate whether endogenous 
human PEPT1 mRNA levels are regulated by PPARα, PPARγ or RXRα. The human 
colon cancer cell line Caco-2 was chosen for this purpose because it expresses 
PPARα, PPARγ and RXRα, all at detectable levels. The cells were treated over 48 
hours with pools of siRNAs specifically targeting one or two transcription factors. 
For the control groups, non-targeting siRNA pools were used. The mRNA levels of 
RXRα, PPARα and PPARγ were measured by real time PCR and the results were 
normalized to beta-actin. Upon RXRα, RXRα/PPARα or RXRα/PPARγ siRNA 
treatment, there was a significant loss of endogenous RXRα mRNA (Fig. 12 A). Both 
PPARα and PPARγ mRNA levels were significantly reduced upon the siRNA 
treatment (Fig. 12 B and C). 
 
A 
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Fig. 12 A-C: Relative RXRα, PPARα and PPARγ mRNA quantification with real-time 
PCR in Caco-2 cells treated with siRNA inhibiting the expression of RXRα, PPARα 
and PPARγ. ***, p < 0.001. 
 
 
7.1.12 Relative ASBT mRNA quantification with real-time PCR in Caco-2 cells 
treated with siRNA inhibiting the expression of RXRα, PPARα and PPARγ 
 
To assess the consequence of markedly reduced levels of RXRα, PPARα and 
PPARγ mRNA expression, ASBT mRNA levels serving as the positive control were 
detected by real-time PCR and normalized to beta-actin. Upon PPARγ, 
PPARα/RXRα and PPARγ/RXRα siRNA treatment, the ASBT mRNA expression 
was significantly reduced (Jung et al., 2002). Both RXRα and PPARα alone did not 
alter the ASBT mRNA expression (Fig. 13). 
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Fig. 13: ASBT mRNA quantification with real-time PCR in Caco-2 cells treated with 
siRNA inhibiting the expression of RXRα, PPARα and PPARγ. ***, p < 0.001, n.s., not 
significant. 
 
 
7.1.13 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
treated with siRNA inhibiting the expression of RXRα, PPARα and PPARγ 
 
After verification that the treatment of Caco-2 cells with siRNA targeting RXRα and 
PPARα expressions reduces the mRNA levels of ASBT (Figure 13), the mRNA levels 
of PEPT1 were determined and normalized to beta-actin. RXRα, PPARα and PPARγ, 
alone or in combination, did not alter the expression of PEPT1 mRNA (Fig. 14). 
 
 
 
Fig. 14: PEPT1 mRNA quantification with real-time PCR in Caco-2 cells treated with 
siRNA inhibiting the expression of RXRα, PPARα and PPARγ.  
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7.1.14 Relative HNF4α mRNA quantification with real-time PCR in Caco-2 cells 
treated with siRNA inhibiting the expression of RXRα, PPARα, PPARγ and 
HNF4α 
 
The hepatocyte nuclear factor 4α (HNF4α) binds like PPARs to DR-1 like DNA 
response elements in order to control the transcription of genes. Knockdown 
experiments with siRNA inhibiting HNF4α as well as RXRα, PPARα and PPARγ 
were performed to study a potential involvement in the transcriptional regulation of 
PEPT1. Caco-2 cells were transfected with inhibiting RNA as mentioned above and 
the measured real-time PCR signals were normalized to beta-actin. The knockdown 
of the HNF4α mRNA was significantly lower when 80 nM of HNF4α specific siRNA 
in combination with PPARα/RXRα or PPARγ/RXRα inhibiting RNA were 
transfected (Fig. 15). It can be assumed the mechanism inhibiting HNF4α mRNA 
expression by interfering siRNA is concentration dependent. 
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Fig. 15: HNF4α mRNA quantification with real-time PCR in Caco-2 cells treated with 
siRNA inhibiting the expression of HNF4α, RXRα, PPARα and PPARγ. ***, p < 0.001, 
n.s., not significant. 
 
 
7.1.15 Relative RXRα, PPARα and PPARγ mRNA quantification with real-time 
PCR in Caco-2 cells treated with siRNA inhibiting the expression of RXRα, 
PPARα, PPARγ and HNF4α 
 
The knockdown of RXRα, PPARα and PPARγ mRNA was confirmed by real-
time PCR and normalizing the results to beta-actin. A significant reduction of the 
mRNA was observed after treating the cells with the siRNA indicated below (Fig. 16 
A-C), except for PPARγ after treating the cells with 40 nM HNF4α siRNA (Fig. 16 C). 
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Fig. 16 A-C: RXRα, PPARα and PPARγ mRNA quantification with real-time PCR in 
Caco-2 cells treated with siRNA inhibiting the expression of HNF4α, RXRα, PPARα 
and PPARγ. ***, p < 0.001, n.s., not significant. 
 
 
7.1.16 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 cells 
treated with siRNA inhibiting the expression of RXRα, PPARα, PPARγ and 
HNF4α 
 
After the verification of the knockdown of the four transcription factors, 
PEPT1 mRNA levels were measured and normalized to beta-actin. The decrease in 
the mRNA of RXRα, PPARα, PPARγ and HNF4α did not affect the mRNA levels of 
PEPT1 (Fig. 17). 
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Fig. 17: PEPT1 mRNA quantification with real-time PCR in Caco-2 cells treated with 
siRNA inhibiting the expression of RXRα, PPARα, PPARγ and HNF4α.  
 
 
7.1.17 Relative PEPT1 mRNA quantification with real-time PCR in Caco-2 
transfected with expression plasmid of PPARγ and RXRα and their respective 
ligands 
 
Caco-2 cells were co-transfected with expression plasmids bearing the PPARγ 
or RXRα coding gene 24 hours prior to the treatment with the corresponding ligands. 
Transfections were performed at a confluency of 70% with 3 µl FuGENE HD/µg 
DNA. 2 µg of each plasmid were used to transfect cells in Corning 12-well plates. The 
cells were harvested after 12 – 16 hours incubation in cell culture medium 
supplemented with 1 µM 15d-PGJ2, 10 µM 9-cis-RA and 1 µM 15d-PGJ2/10 µM 9-cis-
RA. The mRNA was relatively quantified and compared to the control cells treated 
with the vehicle DMSO. 15d-PGJ2 increased the expression of PEPT1 mRNA 
significantly. The addition of 9-cis-RA alone showed no effect, whereas the 
combination of both ligands led to the highest relative mRNA expression (Fig. 18).  
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Fig. 18: Caco-2 cells co-transfected with expression plasmids bearing the PPARγ or 
RXRα coding gene 24 hours prior to the treatment with 1 µM 15d-PGJ2, 10 µM 9-cis-
RA and 1 µM 15d-PGJ2/10 µM 9-cis-RA. ***, p < 0.001, **, p < 0.01, n.s., not 
significant. 
 
 
7.1.18 Relative ASBT mRNA quantification with real-time PCR in Caco-2 cells co-
transfected with expression plasmid of PPARγ and RXRα and their respective 
ligands 
 
According to Jung and co-workers it is known that the expression of ASBT is 
positively regulated by PPARα:RXRα heterodimers (Jung et al., 2002). As the DNA 
consensus region for PPARα:RXRα is similar for PPARγ:RXRα heterodimers, the 
relative mRNA levels of ASBT in Caco-2 cells of the previous experiment were 
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determined as positive control. The combination of 15d-PGJ2 and 9-cis-RA increased 
the expression of ASBT mRNA significantly. The addition of 15d-PGJ2 or 9-cis-RA 
alone did not result in a changed expression. (Fig. 19).  
 
 
 
Fig. 19: Relative mRNA levels of ASBT in Caco-2 cells co-transfected with expression 
plasmids bearing the PPARγ or RXRα coding gene 24 hours prior to the treatment 
with 1 µM 15d-PGJ2, 10 µM 9-cis-RA and 1 µM 15d-PGJ2/10 µM 9-cis-RA. n.s., not 
significant, ***, p < 0.001. 
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7.1.19 Relative PEPT1 mRNA quantification with real-time PCR of rat ileal 
specimens treated with PPARα, PPARγ and RXRα agonists and antagonists 
 
To examine a potential interaction between rat Rxrα, Pparα and Pparγ 
transcription factors and the rat Pept1 promoter ex vivo, rat ileal specimens were 
incubated in cell culture medium containing charcoal stripped fetal bovine serum 
during four hours in a CO2/RH incubator at 37 °C. Charcoal stripped fetal bovine 
serum has been absorbed with activated carbon to remove lipophilic material. The 
reduction of the lipid concentration in the cell medium to a minimum is essential to 
study properly an activation of PPARs by PGs. 20 µM ciprofibrate and 20 µM WY-
14643 were used to activate PPARα, whereas a concentration of 20 µM MK-886 
should antagonize the activation. Troglitazone, 15d-PGJ2 and GW-1929 in a final 
concentration of 20 µM were applied to activate PPARγ. GW-9662 in a concentration 
of 20 µM served as an inhibitor of PPARγ. The samples were treated either with these 
ligands, in combinations of these ligands and upon addition of 1 µM 9-cis-RA that is 
a ligand of RXRα. After four hours incubation period the RNA was isolated, 
transcribed into cDNA and analyzed by real-time PCR. The addition of either Rxrα, 
Pparα and Pparγ agonists or antagonists alone or in their respective combinations 
led to a significant (p < 0.001) increase of rPept1 mRNA. The exclusive addition of 
troglitazone and 15d-PGJ2 showed the smallest increase of rPept1 mRNA (p < 0.1) 
(Fig. 20). 
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Fig. 20: Relative PEPT1 mRNA quantification with real-time PCR of ileal rat explants 
treated with PPARα, PPARγ and RXRα agonists and antagonists. 20 µM of all 
ligands, except 1 µM 9-cis-RA, were used in the treatments. ***, p < 0.001, *, p < 0.1. 
 
 
7.1.20 Relative ASBT mRNA quantification with real-time PCR of ileal rat 
specimens treated with PPARα, PPARγ and RXRα agonists and antagonists 
 
As a positive control the relative mRNA levels of ASBT were determined from 
the previous experiment (see Fig. 19 for the reference). All ligands added exclusively 
or in their respective combinations led to an increased relative ASBT mRNA 
concentration with highest significance (p < 0.001). No change was observed upon 
addition of GW-9662 + 9-cis-RA, WY-14643, troglitazone and 15d-PGJ2 (Fig. 21). 
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Fig. 21: Relative ASBT mRNA quantification with real-time PCR of ileal rat explants 
treated with PPARα, PPARγ and RXRα agonists and antagonists. 9-cis-RA was 
added in a concentration of 1 µM, all the other ligands were 20 µM.  ***, p < 0.001, **, 
p < 0.01. *, p < 0.1. n.s., not significant. 
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7.2 The organic anion transporting polypeptides (Oatps) 
 
All methodologies applied in this study are listed and described in the section 
Materials and Methods. 
 
7.2.1 In silico identification of putative response elements in mouse Slco1a1 and 
Slco1a4 promoters 
 
Organic anion transporting polypeptides (OATPs/Oatps) are important 
membrane transport proteins mediating the sodium-independent transport of bile 
salts, steroid conjugates, thyroid hormones, numerous drugs and xenobiotic 
compounds. Farnesoid X receptor (Fxr) knockout mice fed with bile acids developed 
decreased mRNA levels of Oatp1a1 (formerly Oatp1) in the liver compared to 
wildtype mice (Sinal et al., 2000). In hepatocyte nuclear factor 1α (Hnf1α) and 
hepatocyte nuclear factor 4α (Hnf4α) knockout mice, Oatp1a1mRNA was down 
regulated (Shih et al., 2001, Hayhurst et al., 2001). The Slco1a4 (former Oatp2) gene 
expression was decreased in Hnf1α knockout mice and increased by activation of the 
pregnane X receptor (Pxr) (Shih et al., 2001, Staudinger et al., 2001). However, the 
detailed molecular mechanisms leading to the activation or silencing of Slco1a1 and 
Slco1a4 promoters in rodents remain to be elucidated. To obtain insights into the 
regulation processes, several constructs of both promoters (NCBI accession number: 
NW_001030820) were cloned to identify the transcription factor binding sites 
involved in the promoter regulation using luciferase reporter assays and EMSAs (Fig. 
22 and Fig. 23). 
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Fig. 22: Mouse Slco1a1 promoter sequences and constructs. The parts of the 
promoters cloned into luciferase reporter vectors are indicated by their terminal 
nucleotides. The 5’-end and the 3’-end of the cloned constructs are indicated with -/+ 
in relation to the start of transcription. The longest shown promoter sequence 
represents the template used to clone the constructs. Yellow boxes: putative binding 
sites of transcription factor, green boxes: start of translation (ATG), IR-3: inverted 
repeat with a 3 nucleotide spacer, DR-3: direct repeat with a 3 nucleotide spacer, DR-
4: direct repeat with a 4 nucleotide spacer, DR-6: direct repeat with a 6 nucleotide 
spacer. 
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Fig. 23: Mouse Slco1a4 promoter sequences and constructs. The parts of the 
promoters cloned into luciferase reporter vectors are indicated by their terminal 
nucleotides. The 5’-end and the 3’-end of the cloned constructs are indicated with -/+ 
in relation to the start of transcription. The longest shown promoter sequence 
represents the template used to clone the constructs. Yellow boxes: binding sites of 
transcription factors, green boxes: start of translation (ATG), IR-3: inverted repeat 
with a 3 nucleotide spacer, DR-1: direct repeat with a 1 nucleotide spacer, DR-4: 
direct repeat with a 4 nucleotide spacer, DR-9: direct repeat with a 9 nucleotide 
spacer, DR-10: direct repeat with a 10 nucleotide spacer ER-4: everted repeat with a 4 
nucleotide spacer. 
 
 
7.2.2 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by the human 
glucocorticoid receptor (GR) 
 
The mSlco1a1 (-1991/+202), mSlco1a1 (-553/+202) and mSlco1a1 (-439/+202) 
promoters linked to luciferase reporter genes were co-transfected together with the 
human GR expressing plasmid pSG5-GR into the human liver derived cell line HuH-
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7, and the mouse liver cell line TIB-75. A final concentration of 200 nM 
dexamethasone was used to activate GR. The promoter fragment of the human 
sodium taurocholate co-transporting polypeptide (NTCP) known to be activated by 
GR in the presence of dexamethasone served as a positive control (Eloranta et al., 
2006).  In mouse liver derived TIB-75 cells, the mSlco1a1 (-1991/+202) promoter 
construct covering the DR-3, DR-4 or DR-6 repeats was 1.2 fold activated. The 
mSlco1a1 (-439/+202) promoter fragment which did not contain any predicted 
response element showed also an increased activity. The promoter was not activated 
by the DR-3 or DR-6 element present in the mSlco1a1 (-553/+202) construct. The 
positive control NTCP (-178/+67) showed a 1.4 fold increased activity (Fig. 24 A).  
The mSlco1a4 (-1013/+48) construct was significantly activated whereas the 
longer promoter fragments and the positive control did not show an increased 
activity compared to the negative control (Fig. 24 B).  
In HuH-7 cells the mSlco1a1 (-1991/+202) promoter construct had a tendency 
to higher activity whereas the shorter fragments did not show any significant effects. 
All mSlco1a4 constructs were not activated by GR. The positive controls were 
activated significantly in both experiments (Fig. 24 C and D). 
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Fig. 24 A-D: Co-transfections of TIB-75 and HuH-7 cells with mSlco1a1 and mSlco1a4 
promoter constructs and GR expressing plasmids in the presence of 200 nM 
dexamethasone. ***, p < 0.001; **, p < 0.01; *, p < 0.1; n.s., not significant. 
 
 
7.2.3 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by the mouse 
glucocorticoid receptor (mGr) 
 
In the experiments described above, the human glucocorticoid receptor was 
used to examine mouse promoter sequences in a rodent cell line. The mouse 
glucocorticoid receptor (mGr) was cloned into the expression vector pSG5 to 
investigate whether mouse specific transcriptional regulation mechanisms would 
occur. The mSlco1a1 (-4282/+202) and mSlco1a4 (-4074/+48) promoters were co-
transfected together with pSG5-mGr into TIB-75 and HuH-7 cells. In the presence of 
the ligand dexamethasone in a final concentration of 200 nM, mGr activated in the 
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mouse liver cell line the mSlco1a1 construct 1.2 fold, but not mSlco1a4 (Fig. 25 A). In 
HuH-7 cells both constructs were significantly activated (Fig. 25 B). 
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Fig. 25 A and B: Transactivation of the mouse Slco1a1 and Slco1a4 promoters by the 
mouse glucocorticoid receptor (mGr) in TIB-75 and HuH-7 cells in the presence of 
200 nM of its ligand dexamethasone. ***, p < 0.001; *, p < 0.1; n.s., not significant. 
 
 
7.2.4 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by the mouse 
mPxr:mRxrα heterodimer 
 
The human pregnane X receptor (PXR) interacts with RXRα to form 
heterodimers and recognizes DR-3, DR-4 or ER-6 elements of promoters (Vyhlidal et 
al., 2004). The mouse isoforms of PXR and RXRα were employed in the co-
transfection assays. Increasing final concentrations from 10 µM to 100 µM of 
pregnenolone-16α-carbonitrile (PCN), a rodent Pxr activator, were tested. The 
mSlco1a1 (-4282/+202) promoter was significantly activated in TIB-75 cells only in 
the presence of 50 µM PCN (Fig 26 A). In HuH-7 cells the promoter showed 
increased activity when treated with 10 µM and 100 µM but not with 50 µM PCN (Fig 
26 B). The mSlco1a4 promoter showed a small increase in TIB-75 cells but not in 
human HuH-7 cells (Fig 26 A and B). 
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Fig. 26 A and B: Co-transactivation of the mouse Slco1a1 and Slco1a4 promoters by 
the mPxr:mRxrα heterodimer in TIB-75 and HuH-7 cells. Concentrations of  
10 µM, 50 µM and 100 µM of the rodent Pxr activator pregnenolone-16α-carbonitrile 
(PCN) were tested. ***, p < 0.001; **, p < 0.01; *, p < 0.1. 
 
 
7.2.5 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by the mouse 
mPxr:mRxrα heterodimer and mGr 
 
As a further in vitro model system to study the promoter activities, HepG2 
cells, a human hepatoblastoma cell line, were used in co-transfection assays. Neither 
mSlco1a1 nor mSlco1a4 was significantly activated by mPxr:mRxrα or mGr in the 
presence of their respective ligands, 10 µM PCN or 200 nM dexamethasone (Fig. 27). 
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Fig. 27: Co-transactivation of the mouse Slco1a1 and Slco1a4 promoters by 
mPxr:mRxrα heterodimer and mGr. Final concentrations of 10 µM PCN or 200 nM 
dexamethasone were used to activate mPxr or mGr. 
 
 
7.2.6 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by FXR 
 
The preferred DNA-binding sequence of FXR is an ‘inverted-repeat 1’ (IR-1), 
to which FXR binds as a heterodimer together with RXRα. The ability of this 
heterodimer to activate the mSlco1a1 and mSlco1a4 promoter was examined with co-
transfections of TIB-75, HuH-7 and HepG2 cells. Final concentrations of 50 µM 
chenodeoxycholic acid (CDCA) and 1 µM 9-cis-RA were used to activate FXR and 
RXRα, respectively. In TIB-75 and HuH-7 cells, the mSlco1a1 promoter was not 
activated, whereas the mSlco1a4 promoter activity was decreased significantly (Fig. 
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28 A and B). A trend to activation was found in HepG2 cells that, however, was not 
significant (Fig. 28 C). 
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Fig. 28 A - C: Transactivation of the mouse Slco1a1 and Slco1a4 promoters by FXR. 
Final concentrations of 50 µM chenodeoxycholic acid (CDCA) and 1 µM 9-cis-RA 
were used to activate FXR and RXRα, respectively. **, p < 0.01; n.s., not significant. 
 
 
7.2.7 Transactivation of the mouse Slco1a1 and Slco1a4 promoters by mShp 
 
The small heterodimer partner (SHP) contains the dimerization and ligand-
binding domain found in transcription factors, but lacks the conserved DNA-binding 
domain. SHP negatively interacts with other nuclear receptor superfamily members, 
such as FXR and inhibits transactivation by these receptors. The apoptosis inducer 
AHPN (6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid) is a 
known activator of SHP gene expression. The promoter activities in the presence of 
mouse Shp (mShp) and 5 µM AHPN were studied in TIB-75, HuH-7 and HepG2 
cells. The activity of mSlco1a1 in TIB-75 cells was significantly increased in the 
presence of mShp alone or with its ligand AHPN (Fig. 29 A), whereas no activation 
was observed in HuH-7 and HepG2 cells (Fig. 29 B and C). The mSlco1a4 promoter 
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did not respond significantly in all three cell lines to either mShp, or mShp and 
AHPN (Fig. 29 A – C). 
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Fig. 29 A - C: mSlco1a1 and mSlco1a4 promoter activities in the presence of mShp 
with or without 5 µM of its ligand AHPN in TIB-75, HuH-7 and HepG2 cells. ***, p < 
0.001; **, p < 0.01; n.s., not significant. 
 
 
7.2.8 mOatp1a1 and mOatp1a4 mRNA quantification with real-time PCR of 
mouse liver specimens treated with mPxr and mGr agonists and antagonists 
 
Immortalized cell lines may lose or gain factors or enzymes due to their 
artificial modifications. Taking this fact into account ex vivo samples of mouse livers 
were taken and treated with ligands of transcription factors. Liver specimens of 
C57BL/6 and 129S6 mice were incubated in cell culture medium during 4 hours in a 
CO2/RH incubator at 37 °C. The incubation medium contained 1 µM mifepristone to 
inactivate or 200 nM dexamethasone to activate mGr. 2 µM dexamethasone, 10 µM 
PCN or 400 µM hyperforin were used to activate mPxr. The concentration of 
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mOatp1a1 mRNA was significantly induced in liver specimens of C57BL/6 mice 
upon treatment with mifepristone, dexamethasone or PCN, but not upon addition of 
hyperforin (Fig. 30 A). Dexamethasone and PCN induced the expression of 
mOatp1a4 mRNA. Both mifepristone and hyperforin did not affect the 
transcriptional regulation (Fi.30 B). In 129S6 mice, mOatp1a1 mRNA showed 
increased expression after treatment with dexamethasone and PCN, whereas 
mifepristone or hyperforin did not change the expression (Fig.30 C). The relative 
concentration of mOatp1a4 mRNA exhibited no significant changes after the 
treatments of 129S6 mice liver samples (Fig. 30 D). 
 
A   mOatp1a1mRNA in liver specimens of C57BL/6 mice 
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B   mOatp1a4mRNA in liver specimens of C57BL/6 mice 
 
 
C   mOatp1a1 mRNA in liver specimens of 129S6 mice 
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D   mOatp1a4 mRNA in liver specimens of 129S6 mice 
 
 
Fig. 30 A-D: Relative mRNA expression of the mSlco1a1 and mSlco1a4 genes in liver 
specimens of C57BL/6 and 129S6 mice. Liver specimens of C57BL/6 and 129S6 mice 
were incubated in cell culture medium for 4 hours in a CO2/RH incubator at  
37 °C. The incubation medium contained 1 µM mifepristone to inactivate or 200 nM 
dexamethasone to activate the mGr. To activate mPxr, 2 µM dexamethasone,  
10 µM PCN or 400 µM hyperforin were used. ***, p < 0.001; **, p < 0.01; *, p < 0.1; n.s., 
not significant. 
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8 Discussion 
 
8.1 The peptide transporter 1 (PEPT1/Pept1) 
 
The role of the PEPT1 transporter for the uptake of di- and tripeptides and 
peptidomimetic drugs from the intestinal lumen underscores the importance of 
understanding the mechanisms that govern the transcriptional regulation of the 
PEPT1 gene. Currently it is known that the transcription of the PEPT1 gene is 
regulated by the protein composition of the nutrition (Erickson et al., 1995, Shiraga et 
al., 1999), starvation (Habold et al., 2007), hormones like thyroid hormones (Ashida 
et al., 2002 and 2004) and leptin (Buyse et al., 2001), by diabetes (Gangopadhyay et 
al., 2002), EGF (Nielsen et al., 2001), Ca2+ (Wenzel et al., 2002) and cytokines such as 
TNFα and IFNγ (Vavricka et al., 2006). Shimakura and co-workers showed that the 
treatment of Caco-2 cells with the PPARα ligand WY-14643 led to increased PEPT1 
mRNA levels and an increased uptake of the PEPT1 substrate glycylsarcosine 
(Shimakura et al., 2006). Furthermore an increase of Pept1 mRNA during fasting was 
not observed in PPARα knockout mice compared to wildtype mice. These 
observations suggest a role of PPARα in the transcriptional regulation of 
PEPT1/Pept1. Another prominent member of the PPAR subfamily of nuclear 
receptors is PPARγ. It is yet unknown whether PPARγ regulates the expression of 
PEPT1 or not. Both PPARα and PPARγ bind as heterodimers together with the 
nuclear receptor RXRα to palindromic response elements. These response elements 
are characterized as direct repeats of hexamers with one nucleotide as spacer within 
a promoter of a target gene (Everett et al., 2000, Rosen and Spiegelman, 2001). 
Considering that both transcription factors bind to the same consensus DNA region, 
it is not yet fully understood how PPARα and PPARγ differentiate in terms of their 
specific actions. The nucleotidal composition and the sequence of the nucleotides 
which form the PPREs may play a role whether a PPARα:RXRα or PPARγ:RXRα 
heterodimer binds to this element.  
In silico analysis of the human and rodent PEPT1/Pept1 promoters revealed 
that the human and rat promoter both have a PPRE at nearly the same position 
upstream of the transcriptional start site, designated (-1512/-1500) in the human and 
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(-1487/-1475) in the rat promoter. In addition, the human promoter has a second 
PPRE at position (-401/-389) which could not be found in the rat promoter. The 
mouse promoter has four PPREs at different locations compared to the human or rat 
promoter relative to the transcriptional start site.  
Currently it is hypothesized that PPARs are located in the cytoplasm in their 
inactivated state and are bound to repressor proteins (Scher and Pillinger, 2005). The 
binding of agonistic PPAR ligands leads to the dissociation of these complexes and 
the PPARs translocate to the nuclei where the interaction with RXRα occurs. 
Agonistic PPARγ ligands are thiazolidinediones used in the treatment of diabetes 
mellitus type 2, fibrates regulating hypercholesterolemia , and the naturally 
occurring 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2). 15d-PGJ2 is a 
cyclopentenone prostaglandin that contributes like all prostaglandins (PGs) to 
inflammation, smooth muscle tone, hemostasis, and gastrointestinal secretion, 
amongst others. PGs are rapidly enzymatically inactivated and act therefore mostly 
as autocrine or paracrine signaling molecules. PGs exert their inflammatory and anti-
inflammatory functions via extracellular or intracellular receptors (Scher and 
Pillinger, 2005). PGs may be synthesized by the cell itself or taken up from the 
extracellular space. The transport mechanisms of PGs into and out of a cell are not 
known in detail. Narumiya and Fukushima showed that murine leukemia cells 
transport PGs in a Michaelis-Menten kinetic way which indicates an active transport 
system for PGs (Narumiya and Fukushima, 1986). While most PGs have specific 
transmembrane receptors, 15d-PGJ2 seems to interact so far only with intracellular 
receptors such as PPARs (Scher and Pillinger, 2005). First postulated by Ricote and 
co-researchers, it is today known that 15d-PGJ2 is a ligand of PPARγ (Ricote et al., 
1998). After ligand binding of PPARγ and dislocation from the cytoplasma to the 
nucleus, the complex forms a heterodimer together with RXRα which is activated by 
9-cis-RA (Kliewer et al., 1992).  
The PPRE sequence found in transcriptional regulatory regions of genes often 
differ from its perfect consensus AGGTCAnAGGTCA. Comparing the human PPAR 
response elements at position (-389/-410) and (-1500/-1512) in the regulatory region 
of the PEPT1 gene, nine nucleotides of the first PPRE and eight nucleotides of the 
second PPRE match the perfect consensus sequence. The four PPRE of the mouse 
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Pept1 promoter have between three and five nucleotides and the PPRE of the rat 
Pept1 gene has 4 nucleotides matching AGGTCAnAGGTCA. The first guanine and 
cytosine in the first and second half site of AGGTCAnAGGTCA are conserved 
between the human PPRE (-389/-402) and the rat PPRE (-1475/-1487) and led to the 
highest activations in co-transfection assays. This led to the assumption that both 
PPRE are essential for the overexpression of PEPT1 and rPept1 mRNA.  
The loss of activation found for the PEPT1 (-65/+57) construct in co-
transfection assays is consistent with this assumption. In contrast the           
rPept1(-1048/+20) construct was significantly activated even though in silico analysis 
by MATInspector and NUBIScan and visual search for potential PPREs in this 
promoter construct was not successful. All mPept1 promoter constructs were not 
significantly activated. The absence in the mPept1 promoter of the nucleotides 
conserved between humans and rats PPREs may be the reason for the non-response 
in co-transfections of the mouse promoter constructs. EMSAs showed binding of in 
vitro translated PPARγ and RXRα as heterodimers to the human PPRE at position     
(-1500/-1512) and to the rat PPRE at position (-1475/-1487). The rat PPRE bound 
quantitatively more PPARγ:RXRα heterodimers than the human PPRE. Both PPREs 
were not bound by combinations of pSG5 and either PPARγ or RXRα or by pSG5 
alone. 
The ASBT PPRE used as positive control has the sequence 
AGGCCAgAGGTCA and has consequently only one nucleotide that is different from 
the perfect PPRE sequence. The four selected mouse PPREs did not interact with any 
in vitro translated protein. The EMSA results obtained support the observations made 
in co-transfection assays that the human and rat PEPT1 promoter but not the mouse 
promoter interacts with PPARγ:RXRα heterodimers.  
In a further step Caco-2 cells were treated with 15d-PGJ2 and 9-cis-RA to activate 
PPARγ and RXRα followed by an extraction of these protein complexes from the 
nuclei. These nuclear protein extracts were used instead of in vitro translated proteins 
in EMSAs to examine the interaction of PPARγ:RXRα heterodimers from living cells 
with the DNA. The visualization of the protein complexes bound to the PPREs 
displayed so-called smearing bands indicating that not a single protein type or 
protein complex binds to the DNA but several different proteins or protein 
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complexes. It may be that the PPREs were bound by other proteins or protein 
complexes different from the PPARγ:RXRα heterodimers. The use of PPARγ or RXRα 
antibodies did not result in a supershift of bands which means that the antibodies 
did not interact with the nuclear extracts. Both PPARγ and both RXRα antibodies 
should interact with their antigens according to the literature (Lii et al., 2012, Yuan et 
al., 2012, Childs et al., 2011, Adhikary et al., 2011).  
A further step to gain insight into a possible binding of PPARγ:RXRα 
heterodimers to PPREs in the PEPT1/rPept1 promoters is to mutate nucleotides of 
the PPREs which are essential for the binding of PPARγ:RXRα heterodimers (Okuno 
et al., 2001). Point mutations exchanged these nucleotides of the human PPREs          
(-389/-401) and (-1500/-1512) and the rat PPRE (-1475/-1487), and the mutated 
PPREs and promoter constructs were tested for their abilities to bind PPARγ:RXRα 
heterodimers. In co-transfection assays there was no decrease in activation of 
promoter constructs featuring either one or all mutated human and rat PPREs 
compared to the promoter constructs with the wild-type PPREs. PPARγ:RXRα 
heterodimers either still interacted to a sufficient degree with the mutated DR-1 
sequence or alternatively bound to a DR-1 like element at a different position not 
affected by the mutation. 
To study a possible interaction between the PEPT1 promoter and the 
transcription factors PPARγ and RXRα within living cells, the endogenous relative 
mRNA levels of the genes of interest were first determined in Caco-2, DLD-1, T84, 
LS174T and HT-29 cells to select a suitable cell line. Caco-2 cells expressed by far the 
highest concentrations of PEPT1 mRNA followed by T84 cells. DLD-1, LS174T and 
HT-29 had very low or even undetectable levels of PEPT1 mRNA. Even though 
PEPT1 mRNA is found primarily only in the small intestine, the human colon 
derived cell line Caco-2 expresses the PEPT1 transporter (Brandsch et al., 1994). The 
PEPT1 mRNA detection in Caco-2 cells is in consistence with the study of Brandsch 
and co-workers. The differences in the expression of PPARα, PPARγ and RXRα 
mRNA were not as distinctive as of PEPT1 mRNA in the cell lines. PPARα was 
included in the studies to examine the possibility of a PPARα interaction with the 
PEPT1 promoter as a heterodimer together with RXRα. PPARα:RXRα binds like 
PPARγ:RXRα heterodimers to DR-1 motifs of the DNA and regulates the 
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transcription of genes (Keller et al., 1993). The Caco-2 cells were chosen as cell line for 
further studies because of the high PEPT1 mRNA levels and the similar expression of 
PPARα, PPARγ and RXRα mRNA expression levels compared to the other cell lines. 
Additionally, Caco-2 cells were already used in co-transfection assays. 
The 48-hour incubation of Caco-2 cells with the agonists of RXRα, 9-cis-RA, 
the agonist of PPARγ, 15d-PGJ2, and the antagonist of PPARγ, GW-9662, alone 
showed no alterations in the PEPT1 mRNA levels. The combination of 15d-PGJ2 and 
GW-9662 did not change the expression, whereas the combination of 15d-PGJ2 and 9-
cis-RA led to lower levels of PEPT1 mRNA compared to the cells treated with the 
solvent of the ligands. Natural agonists for PPARγ are free fatty acids (Dreyer et al., 
1993). They are components of bovine serum which is a supplement in cell culture to 
support the proliferation of tissue cells. To exclude an activation of endogenous 
PPARγ by these fatty acids, delipidated serum was used in a further experiment. The 
mRNA levels of PEPT1 showed still the same levels as the result obtained with cells 
treated with normal cell culture medium. On the one hand, there are two main 
problems with incubations over a 48-hour time period that can occur caused by the 
different dynamics of the participating compounds involved in the regulation. First, 
the ligands used to stimulate the transcription are rapidly deactivated, which is the 
case for many prostaglandins like 15d-PGJ2. Second, an overexpression of a certain 
gene by endogenous or exogenous compounds may activate feedback mechanisms 
down-regulating the ‘abnormal’ expression over time. On the other hand, the 
transcriptional machinery needs a certain time period to be activated and to 
synthesize the mRNA.  
These considerations resulted in an experiment in which a reduction of the 
incubation period to 24 hours was tested. This experiment showed the importance of 
the incubation period for the mRNA levels detected which were rather different from 
the 48 hours treatment. Caco-2 cells cultured in normal tissue medium and treated 
with 15d-PGJ2 alone or in combination with the antagonist GW-9662 had the 
tendency to higher PEPT1 mRNA levels rather than the control cells. 9-cis-RA alone 
or in combination with 15d-PGJ2 had lower levels, and GW-9662 alone resulted in 
PEPT1 mRNA levels that were not significantly different from the control. Cells in 
delipidated cell culture medium and treated with the antagonist GW-9662 alone 
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developed significantly higher PEPT1 mRNA levels. All other treatments resulted in 
lower or unchanged PEPT1 mRNA levels. Due to these inconsistent results analysis 
of the exact role of PPARγ and RXRα in the transcriptional regulation of PEPT1 in 
Caco-2 cells will require further investigation. 
Even though Caco-2 cells express PPARγ and RXRα at certain levels shown by 
mRNA quantification, expression plasmids that contained the coding sequences of 
both transcription factors were transfected into Caco-2 cells to enhance intracellular 
concentrations of PPARγ and RXRα proteins. Twenty four hours after the 
transfection, the agonistic ligands of PPARγ and RXRα, 15d-PGJ2 and 9-cis-RA, 
respectively, were added to the medium and the PEPT1 mRNA levels were 
measured after another twenty four hours. The addition of 15d-PGJ2 led to a 
significant increase in PEPT1 mRNA compared to the cells treated with the solvent of 
15d-PGJ2. The combination of 15d-PGJ2 and 9-cis-RA augmented the concentration 
of PEPT1 mRNA compared to the cells treated with 15d-PGJ2 only. The addition of 9-
cis-RA alone had no influence on the PEPT1 mRNA levels.  
According to Jung and co-workers, PPARα regulates together with its 
heterodimeric partner RXRα the expression of ASBT mRNA in Caco-2 cells (Jung et 
al., 2002). This was confirmed in co-transfection assays of the ASBT promoter and 
PPARα and RXRα expression plasmids, in EMSAs with in vitro translated PPARα 
and RXRα and by induction of ASBT mRNA expression via addition of the PPARα 
agonist ciprofibrate to SK-ChA cholangiocytes. Due to the fact that both 
PPARα:RXRα and PPARγ:RXRα heterodimers bind DR-1 like motifs in promoter 
sequences, the ASBT mRNA levels of the treated cells were used as positive control. 
The PEPT1 mRNA levels of the cells treated with 15d-PGJ2 and 9-cis-RA increased 
~2 fold, whereas the addition of the ligands alone showed an increase in PEPT1 
mRNA of maximum ~1.3 fold. Despite several lines of evidence that indicate an 
induction of PEPT1 mRNA transcription in Caco-2 cells co-transfected with PPARγ 
and RXRα expression plasmids, some aspects regarding the interaction of 
PPARγ:RXRα heterodimers and the PEPT1 promoter remain unclear.  
Another assay to analyze the influence of transcription factors on gene 
expression would be to knockdown certain transcription factors and as a 
consequence reduce the transcription of genes regulated by the affected transcription 
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factors. For these assays Caco-2 cells were used because they express RXRα, PPARα 
and PPARγ proteins at detectable levels. The knockdown of all three transcription 
factors alone or in combination was verified by real-time PCR. To test the functioning 
of the method, first mRNA levels of ASBT were detected in Caco-2 cells treated with 
RXRα and PPARα siRNA. The mRNA levels of ASBT in Caco-2 cells treated with 
RXRα and PPARα siRNA were significantly lowered, which confirms the hypothesis 
of Jung and co-researchers (Jung et al., 2002). However the knockdown of RXRα, 
PPARα, PPARγ and its two heterodimeric variations did not alter the expression of 
PEPT1 mRNA.  
HNF4α is a liver-enriched nuclear transcription factor and interacts with DR-1 
motifs, but, unlike the PPARs, it forms a homodimer which binds to DNA (Jiang et 
al., 1995). A possible interplay of HNF4α and RXRα, PPARα and PPARγ was 
examined with siRNA targeting these transcription factors in Caco-2 cells. This 
knockdown experiment showed a slight, but not significant, decrease of PEPT1 
mRNA in Caco-2 cells treated with 80 nM concentrations of HNF4α siRNA and 80 
nM and 40 nM concentrations of PPARα and RXRα siRNA, respectively. Lower 
concentrations of HNF4α siRNA or combinations with PPARγ siRNA did not have 
an influence on the expression of PEPT1 mRNA. The unchanged PEPT1 mRNA in 
Caco-2 cells treated with the siRNA targeting the transcription factors as compared 
to the concentration of PEPT1 mRNA in cells treated with non-targeting control 
siRNA led to the assumption that neither PPARα and PPARγ nor RXRα and HNF4α 
has an important role in the transcriptional regulation of PEPT1.  
A possible interaction between rat Rxrα, Pparα and Pparγ and the rat Pept1 
promoter was analyzed by treating ex vivo ileal specimens of rats with corresponding 
agonists and antagonists. Ex vivo treatment of intestinal rat specimens was 
previously successfully established in our laboratory (Eloranta et al., 2009). Duodenal 
rat specimens were treated during eight hours with vitamin D3 which resulted in an 
increased expression of proton coupled folate transporter mRNA. To analyze the rat 
Pept1 mRNA expression, the specimens were incubated in medium containing 
agonists and/or antagonists of RXRα, PPARα and PPARγ. PPARα agonists WY-
14643 (Reddy et al., 1978) and ciprofibrate (Auwerx, 1992) and the antagonist MK-886 
(Kehrer et al., 2001) were examined. Troglitazone (Lambe and Tugwood, 1996), 15d-
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PGJ2 and GW-1929 (Brown et al., 1999) were used to activate PPARγ. GW-9662 
(Huang et al., 1999) was applied to inhibit the activation of PPARγ. All agonists and 
antagonists of PPARα and PPARγ were added alone or in combination with the 
agonist of RXRα to the medium.  
Surprisingly, all treatments resulted in an increased expression of rat Pept1. 
Addition of the antagonists of PPARα and PPARγ led to similar or even higher Pept1 
mRNA expression than addition of the agonists. The highest activation was observed 
when 9-cis-RA was exclusively added. As positive control, the collected mRNA 
samples were analyzed for their Asbt mRNA expression. The pattern of mRNA 
concentration resembled the concentration of Pept1. These inconsistent results may 
be the consequence of different stabilities of mRNAs of different genes (Kren and 
Steer, 1996). The rate of poly(A) tail removals or the binding of proteins to the 
mRNAs may result in increased or decreased transcript stability. In addition the cells 
are exposed from the moment of taking the sample to extreme stress condition even 
when they are incubated in tissue cell incubators with adjusted temperatures and 
CO2/RH conditions for the cells. These conditions may also contribute to an altered 
mRNA stability. 
 
8.2 The organic anion transporting polypeptides (Oatps) 
 
The organic anion transporting polypeptides (SLCO gene family) are 
characterized by a broad substrate specificity and expression in epithelial cells of 
various tissues. The factors that influence their expression level are of great interest 
due to their potential effect on the pharmacokinetics of the substrates transported 
(for references see introduction) 
In silico analysis revealed that the mouse Slco1a1 promoter covered two DR-3 
response element and one DR-4, DR-6 and IR-3 response element, whereas the 
mouse Slco1a4 promoter covered one DR-1, DR-4, DR-9, DR-10, ER-2 and IR-3 
response element . The glucocorticoid receptor homodimer complex interacts with 
different variations of palindromic consensus sequences with the half site TGTTCT 
(Aumais et al., 1996). These include direct repeats (DR), everted repeats (ER) and 
inverted repeats (IR) of the half site with different numbers of nucleotides as spacer 
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in between. It is known that the mouse Slco1a1 promoter interacts with Hnf1α, Hnf4α 
and Fxr, but whether the glucocorticoid receptor binds to any of the mentioned 
response elements is not known. First results of co-transfection assays in the mouse 
liver-derived cell line TIB-75 showed a significant activation of the mSlco1a1 (-
1991/+202) construct  covering the DR-3, DR-4 and DR-6 response element, whereas 
the mSlco1a1 (-553/+202) construct covering the DR-3 and DR-6 response element 
did not respond to the administration of the human GR and its ligand 
dexamethasone. This would implicate an activation of the mSlco1a1 (-1991/+202) 
construct by the GR. However, the mSlco1a1 (-439/+202) construct covering no 
known GR response element was activated to the same level by GR as mSlco1a1 (-
1991/+202). As positive control the activation of a promoter construct of NTCP by 
GR was confirmed (Eloranta et al., 2006). The activation of the mSlco1a4 constructs 
covering the DR-1, DR-4, ER-2 and IR-3 response elements by the GR were measured 
as well in TIB-75 cells. Surprisingly the shortest promoter construct covering no 
known GR response element was activated with highest significance and the 
promoter constructs covering at least one GR response element were not responsive. 
However this result may be questionable due to the positive control promoter 
construct which showed not the normal activation by GR.  
Repetition of both assays in human liver-derived cells, HuH-7, showed a non-
significant activation of the mSlco1a1 (-1991/+202) construct and a significant 
activation of the positive control, whereas all other mSlco1a1 promoter constructs 
were not activated by GR. The mSlco1a4 promoter constructs did not respond to the 
treatment with GR and its ligand, but the positive control was activated as 
previously shown. So far, the replacement of the mouse liver cell line with a human 
liver cell line did not result in an activation of the mSlco1a1 or mSlco1a4 promoter 
constructs by GR. To avoid a possible incompatibility of the GR with the mouse 
specific cell line TIB-75 or the mouse promoter constructs tested, the mouse specific 
glucocorticoid receptor was cloned and tested in co-transfection assays. In these 
assays the longest promoter constructs of mSlco1a1 and mSlco1a4 were analyzed 
instead of the shorter constructs used previously. The longest mSlco1a1 (-4282/+202) 
promoter construct covered in addition to the mSlco1a1  
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(-1991/+202) construct a DR-3 and IR-3 response element, whereas the longest 
mSlco1a4 (-4074/+48) construct covered additionally to the mSlco1a4 (-3832/+48) 
construct a DR-9 and DR-10 response element. In TIB-75 cells, the mSlco1a1  
(-4282/+202) construct was significantly activated, whereas the mSlco1a4 (-4074/+48) 
construct did not respond to the addition of the mGr and its ligand dexamethasone. 
This is consistent with the results obtained by co-transfection of the shorter 
constructs and the GR in TIB-75 cells. In HuH-7 cells both promoter constructs were 
significantly activated, which is in contrast to the results with the shorter constructs 
in the same cell line.  
Another prominent transcription factor possibly regulating both promoters is 
the PXR due to its binding to DR-3, DR-4 and ER-6 response elements. Both promoter 
constructs were tested in HuH-7 and TIB-75 cells with increasing PCN concentrations 
and the mouse isoforms of PXR, mPxr, and RXRα, mRxrα. The mSlco1a1(-4282/+202) 
construct was significantly activated, whereas the mSlco1a4 (-4074/+48) construct 
had a tendency to higher activity when treated with high concentrations of PCN in 
TIB-75 cells. In HuH-7 cells, only the mSlco1a1 (-4282/+202) promoter was activated 
significantly by the highest and lowest PCN concentration. Co-transfections in a 
further human liver-derived cell line, HepG2, showed that both the longest mSlco1a1 
and mSlco1a4 promoter constructs were activated by mGr and mPxr:mRxrα but not 
in a significant manner. An involvement of human FXR together with its 
heterodimeric partner RXRα or the mShp protein in the presence of its ligands 
CDCA, 9-cis-RA or AHPN in the regulation of both promoters could not be shown in 
co-transfection assay in TIB-75, HuH-7 and HepG2 cells.  
Liver samples of 2 strains of mice, C57BL/6 and 129S6, with agonists and 
antagonists of Gr and Pxr were treated ex vivo during four hours. In C57BL/6 mice, 
both the agonist and the antagonist of Gr induced the mRNA expression of 
mSlco1a1. The activation of Pxr by 2 µM dexamethasone and 10 µM PCN led to 
higher concentrations of mSlco1a1 mRNA, whereas the addition of the Pxr agonist 
hyperforin did not have any effect on the mRNA expression of the mSlco1a1 gene. 
The same pattern of increased mRNA concentrations was observed for the mSlco1a4 
gene except for mifepristone which did not affect the expression of the mSlco1a4 gene 
significantly. The mSlco1a1 mRNA expression was induced in 129S6 mice liver 
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specimens by low and high doses of dexamethasone and PCN, but not by 
mifepristone or hyperforin. The mRNA of the mSlco1a4 gene was not significantly 
increased in the same samples.  
Some results from co-transfection assays or the ex vivo treatment of mouse 
liver specimens would indicate an interaction between the mentioned transcription 
factors and the mSlco1a1 or mSlco1a4 promoters. Nevertheless, a consistent activation 
of mSlco1a1 or mSlco1a4 promoters by PXR/RXRα, mPxr:mRxrα, GR, mGr, FXR or 
mShp was not observed in co-transfection assays or treatment of mouse and human 
liver-derived cell lines with the respective ligands of the transcription factors. 
 
 
9 Future directions 
 
The present thesis gives more details into the mechanisms that control the 
transcriptional regulation of the human and rodent PEPT1/Pept1 gene promoters 
and the mouse Slco1a1 and Slco1a4 gene promoters.  
The described experiments have shown for the first time that PPARγ 
influences together with RXRα the activities of the human and rat PEPT1/Pept1 
promoters. The results obtained point to an involvement of the PPARγ:RXRα 
heterodimer in the transcriptional regulation of the human and rat PEPT1/Pept1 
genes. Although PPARγ:RXRα significantly changed the human and rat 
PEPT1/Pept1 promoter activities, it remains to be elucidated whether other 
transcription factors or signaling pathways contribute to this regulation cascade. 
Further assays are needed to pursue the findings of this study. One point which 
should be considered in future experiments is the effect of PPARγ agonists on the 
PEPT1 protein expression in Caco-2 cells. Such experiments would give more details 
about the functional transport of PEPT1 substrates. Although the changes of PEPT1 
promoter activity were significant, it is questionable whether these regulations are 
sufficient to fully explain the activity changes of the PEPT1 protein in the apical 
membrane of enterocytes. It should be taken into account that regulations at many 
steps from the transcription to the integration of the PEPT1 proteins into the 
phospholipid bilayers are possible. 
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 The examination of the mouse Slco1a1 and Slco1a4 promoters lead to the 
conclusion that the activation of the glucocorticoid receptor by dexamethasone has 
an effect on the transcriptional regulation of both promoters. This was shown in co-
transfection assays measuring the Slco1a1 and Slco1a4 promoter activities by 
luminescence and by treating explants of mouse liver with dexamethasone. These 
results show for the first time that the transcriptional regulation proceeds via the 
glucocorticoid receptor mediated pathway. To acquire more knowledge about the 
involvement of the glucocorticoid receptor in the signaling cascade that activates or 
represses the Slco1a1 or Slco1a4 promoter more detailed molecular analyses are 
needed. 
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10 Contributions to original articles 
 
 Eloranta JJ, Hiller C, Jüttner M, Kullak-Ublick GA (2012) The SLCO1A2 
gene, encoding human organic anion-transporting polypeptide 1A2, is 
transactivated by the vitamin D receptor. Mol Pharmacol 82:37-46 
 
The first Western blot showing an induction of OATP1A2 expression by 
treatment of Caco-2 cells with vitamin D3 was initially done by M Jüttner 
(Figure 1 D). The transfection assays with siRNA specifically targeting VDR in 
Caco-2 cells shown in Figure 2 A and B were established, performed and 
analyzed by M Jüttner. Preliminary experiments showing with ChIP assays 
the interaction of VDR with the vitamin D3-responsive region of the SLCO1A2 
promoter within Caco-2 cells were done by M Jüttner (Figure 5). 
Several transport experiments with OATP1A2 substrates like deltorphin II, 
enkephalin and estrone-3-sulfate were performed to evaluate a potential 
change of OATP1A2 transport activity upon treatment of Caco-2 cells with 
vitamin D3. There was a tendency to an increased transport activity of 
OATP1A2 substrates into Caco-2 cells treated with vitamin D3. The data were 
finally not included in the manuscript.  
 
 
 Ma L, Jüttner M, Kullak-Ublick GA, Eloranta JJ (2012). Regulation of the 
gene encoding the intestinal bile acid transporter ASBT by the caudal-type 
homeobox proteins CDX1 and CDX2. Am J Physiol Gastrointest Liver 
Physiol 302:G123-33 
 
The co-transfections assays in Caco-2 and IEC-4.1 cells comparing the 
human and rodent ASBT/Asbt promoter activation by CDX1 and CDX2 were 
performed and analyzed by M Jüttner (Figure 2 F and G). 
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13 Appendix 
 
Sequences of oligonucleotides used for cloning, site-directed mutagenesis and 
EMSAs 
  
The introduced restriction sites are underlined. The corresponding restriction 
enzyme used is listed for each oligonucleotide. Only the top strands (+) are shown 
for oligonucleotides used in cloning and EMSAs. Both strands (+/-) are shown of the 
oligonucleotides used in site-directed mutagenesis. Point mutations compared to the 
wildtype sequence are red labeled.  
 
- Cloning oligonucleotides 
 
PEPT1 promoter construct 
 
RP:  
ACG CGT GGC GGC GGC TCC CAG GGC     (MluI) 
 
FP (-2010):  
GAG CTC GTG CCT CAG TAA ACA TAT GTG TGC ACG TG  (SacI) 
 
 
mPept1 promoter construct 
 
RP: 
CTC GAG CGA CTG GCA AGC AGG AGT TCA G    (XhoI) 
 
FP (-1095): 
ACG CGT GAA TAT GGC TGA GCC TGG AGA ACA C   (MluI) 
 
 
118 
 
FP (-2150): 
ACG CGT CAA ATT CCC CTC CTC AAC CTC CC    (MluI) 
 
 
rPept1 promoter constructs 
 
RP: 
CTC GAG ACT GGC AAG CAG GAG TTC AGC C    (XhoI) 
  
FP (-1048): 
ACG CGT TGC TAA CTG AAA GAA GCC AGC CAC AG   (MluI) 
 
FP (-1943): 
ACG CGT GAT TTG TTA GAG AAA GAA GCC CAG TGG  (MluI) 
 
 
mSlco1a1 promoter constructs 
 
RP: 
CTC GAG GAT AGA GTG CCT TAG TCA GAG TTT C    (XhoI) 
 
FP (-439): 
GCT AGC GTC TCT TCA TTC AGT TTC TTG GTG GT   (NheI) 
 
FP (-553): 
GCT AGC TCT GTC CAT AAG TAT GTG TGC AGG TG   (NheI) 
 
FP (-1991): 
GCT AGC AGA GCA AGT TTA GAT ATC AAA TCA GCA AC  (NheI) 
 
FP (-3926): 
GCT AGC AAT CCC AGC ACT TTG GAG GCA G    (NheI) 
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FP (-4282): 
GCT AGC GCA CTG GAA ATG TTA ATG AAG GAA ATA CC  (NheI) 
 
 
mSlco1a4 promoter constructs 
 
RP: 
CTC GAG CAA GTG AGA AGT CCA CAC ATG AAG   (XhoI) 
 
FP (-1013): 
GCT AGC GAA CTG AGT GGT CTG TCT AAA CAC AC   (NheI) 
 
FP (-1163): 
GCT AGC TCT CTT CCT GAT ACA GCC TTT AAC G   (NheI) 
 
FP (-1227): 
GCT AGC CCA TCC TAG CTT CCA ATG GTG G    (NheI) 
 
FP (-1672): 
GCT AGC GTA GGG CTG AAT TCA TGA ATC TCA CTC   (NheI) 
 
FP (-3832): 
GCT AGC TGG AGA CAT AGA TAA GGG GCA TTG TG   (NheI) 
 
FP (-4074): 
GCT AGC TTT TCT ATA ACC CAA TGT CTC TTG GAT GC  (NheI) 
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mGr construct (NM_008173.3) 
 
FP: 
 
GCT AGC ATG GAC TCC AAA GAA TCC TTA GCT C   (NheI) 
 
RP: 
 
GGA TCC TCA TTT CTG ATG AAA CAG AAG CTT TTT G  (BamHI)
  
 
- Site-directed mutagenesis oligonucleotides 
 
 
PEPT1 
 
-390 mut +: 
CAG CTG CCA ACC GTC ACA CCG TGT TTT GCC TCC CCA CCC 
 
-390 mut -: 
CAC GGT GTG ACG GTT GGC AGC TGT GTG TGT GTG TGT GTG TGT G 
 
 
1500 mut +: 
CAT ATT TTT GGC CTA CTT TTT GAT GGG GTT GTT TGA TTT TTT TC 
 
1500 mut -: 
CCA TCA AAA AGT AGG CCA AAA ATA TGA ACA GAC CCT TCT CAA AAG 
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rPept1 
 
1495 mut +: 
CCT CAA CAT CAC GAA TTG CAC CCT ACC GAG GAA ACC AAC CAA AGG 
 
1495 mut -: 
CGG TAG GGT GCA ATT CGT GAT GTT GAG GTC CAA AAC TTC GAC ATC 
 
 
- EMSA oligonucleotides 
 
PEPT1 PPREs 
 
-389/-401:   
AGC TAC GGT GGG ACA GTG GTC AGC TGT 
 
-1500/-1512:  
AGC TAA AAG TGG GCA AAG GAT ATG AAC 
     
 
mPept1 PPREs 
 
-1283/-1295:  
AGC TTC CTT TTA CCC TTG AAC TGT TGC 
     
-1762/-1774:  
AGC TGC ATG TGT TCT GTG TCC TGC AGG 
   
-1828/-1840:  
AGC TGT CTA TGT CCT CTA CAC TGA GAG 
     
-1862/-1874:  
122 
 
AGC TGG GCC TCT TCT TTG ACC TCA CTC 
 
  
rPept1 PPRE 
 
-1475/-1487:  
AGC TTA GGG TGA ACT TTG TGC TGT TGA 
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